

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 August 2016 (04.08.2016)

(10) International Publication Number
WO 2016/120850 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) *C07D 401/14* (2006.01)
A61K 31/4439 (2006.01) *C07D 405/14* (2006.01)
A61P 17/06 (2006.01) *C07D 413/14* (2006.01)

(21) International Application Number:

PCT/IB2016/050477

(22) International Filing Date:

29 January 2016 (29.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/110,060 30 January 2015 (30.01.2015) US
62/267,350 15 December 2015 (15.12.2015) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **SCHNUTE, Mark Edward**; 10 Chase Path,
Acton, Massachusetts 01720 (US). **FLICK, Andrew
Christopher**; 3107 Maple Tree Lane, East Lyme, Con-
necticut 06333 (US). **JONES, Peter**; 61 Henderson Street,
Arlington, Massachusetts 02474 (US). **KAILA, Neelu**; 17
Augustus Road, Lexington, Massachusetts 02421 (US).
MENTE, Scot Richard; 48 Arlmont Street, Arlington,
Massachusetts 02476 (US). **TRZUPEK, John David**; 55
Station Landing #515, Medford, Massachusetts 02155
(US). **VAZQUEZ, Michael L.**; 23 Timbercreek Lane,
Billerica, Massachusetts 01821 (US). **XING, Li**; 8 Great
Rock Road, Lexington, Massachusetts 02421 (US).
ZHANG, Liying; 500 Broadway Apt. 2143, Malden, Mas-
sachusetts 02148 (US). **WENNERSTAL, Goran Mattias**;

Sankt Mickelsgatan 149, SE-129 44 Hagersten (SE).
ZAMARATSKI, Edouard; Fredsgatan 2 B, SE-753 13
Uppsala (SE).

(74) Agent: **WALDRON, Roy F.**; PFIZER INC., 235 East
42nd Street, MS 235/9/S20, New York, New York 10017
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SULFONAMIDE-SUBSTITUTED INDOLE MODULATORS OF RORC2 AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-
lopyridines, pharmaceutical compositions thereof, methods of modulating RORy activity and/or reducing the amount of IL-17 in a
subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.



WO 2016/120850 A1

Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof**BACKGROUND OF THE INVENTION**

Retinoid-related orphan receptors (ROR) are reported to have an important role in numerous biological processes. Scientific investigations relating to each of retinoid-related orphan receptors ROR α , ROR β , and ROR γ have been described in the literature. Continuing research in this field is spurred by the promise of developing new therapeutic agents to treat medical disorders associated with retinoid-related orphan receptor activity.


ROR γ has been reported to be expressed in high concentration in various tissues, such as thymus, kidney, liver, muscle, and certain fat tissue. Two isoforms of ROR γ have been identified and are referred to as γ 1 and γ 2 (also referred to as ROR γ t). Expression of the γ 2 isoform has been reported to appear in, for example, double-positive thymocytes. Compounds capable of modulating ROR γ t activity are contemplated to provide a therapeutic benefit in the treatment of multiple medical disorders, including immune and inflammatory disorders.

Numerous immune and inflammatory disorders continue to afflict millions of patients worldwide. Significant advances have been made in treating these disorders. However, current therapies do not provide satisfactory results for all patients due to, for example, detrimental side effects or insufficient efficacy. Treatments for immune and inflammatory disorders vary depending on the particular medical disorder, and often involve use of immunosuppressive drugs. Surgery (e.g., splenectomy), plasmapheresis, or radiation can be used in certain instances.

One exemplary immune disorder in need of better therapy is psoriasis. Psoriasis is a T cell-mediated inflammatory disease that affects approximately 2% to 3% of adults and has a substantial adverse impact on the quality of life for patients suffering from this disorder. Plaques resulting from psoriasis can be painful and are visually unappealing. Various therapeutics have been developed in an attempt to treat psoriasis. However, the traditional therapies for psoriasis often have toxic adverse effects. Accordingly, a need exists for improved treatments for psoriasis as well as other immune and inflammatory disorders.

SUMMARY

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR γ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds. In particular, one aspect of the invention relates to compounds represented by Formula I:



I

and pharmaceutically acceptable salts, pharmaceutically active metabolites, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof; wherein R¹, X and W are
5 as defined in the Detailed Description.

Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as described in the Detailed Description. A large number of disorders may be treated using the
10 compounds described herein. For example, the compounds described herein may be used to treat an immune disorder or inflammatory disorder, such as rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma,
15 ulcerative colitis, asthma, epidermal hyperplasia, and other medical disorders described herein.

DETAILED DESCRIPTION

The invention provides compounds, pharmaceutical compositions, methods of modulating ROR γ activity and/or reducing the amount of IL-17 in a subject, and therapeutic uses of said compounds and pharmaceutical compositions. The practice of the present invention employs,
20 unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in "Comprehensive Organic Synthesis" (B.M. Trost & I. Fleming, eds., 1991-1992); "Handbook of experimental immunology" (D.M. Weir & C.C. Blackwell, eds.); "Current protocols in molecular biology" (F.M. Ausubel *et al.*, eds., 1987, and
25 periodic updates); and "Current protocols in immunology" (J.E. Coligan *et al.*, eds., 1991), each of which is herein incorporated by reference in its entirety.

Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls.

It is to be understood that the foregoing general description and the following detailed
30 description are exemplary and explanatory only and are not restrictive of any subject matter

claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include," "includes," and "included," is not limiting.

It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described herein, which will be limited only by the appended claims.

All publications and patents mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications, which might be used in connection with the methods, compositions and compounds described herein.

Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates.

Definitions

"ROR" stands for Retinoic acid receptor-related Orphan Receptor. There are three forms of ROR, ROR- α , - β , and - γ and each is encoded by a separate gene (RORA, RORB, and RORC respectively). There are two subtypes of RORC: 1 and 2. Subtype 2 is also called "t". The human RORC gene is also called TOR; RORG; RZRG; NRIF3; and RZR-GAMMA. The human protein RORC is also called nuclear receptor ROR-gamma; nuclear receptor RZR-gamma; retinoic acid-binding receptor gamma; retinoid-related orphan receptor gamma; RAR-related orphan receptor C, isoform a; RAR-related orphan nuclear receptor variant 2; nuclear receptor subfamily 1 group F member 3. As used herein, "ROR γ " and "RORC2" are used interchangeably to refer to a protein from a RORC subtype 2 gene.

As used herein, the term "modulator" refers to a compound that alters an activity of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a certain activity of a molecule compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of one or more activities of a molecule. In certain embodiments, an inhibitor completely prevents one or more activities of a molecule. In certain embodiments, a modulator is an activator, which

increases the magnitude of at least one activity of a molecule. In certain embodiments the presence of a modulator results in an activity that does not occur in the absence of the modulator.

The term "alkyl" refers to a substituent obtained by removing a hydrogen from a saturated, straight (i.e. unbranched) or branched carbon chain (or carbon), or combination thereof, which has the number of carbon atoms designated (i.e. C₁-C₆ means one to six carbons). Examples of alkyl substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isoamyl, hexyl and the like.

The term "haloalkyl" is an alkyl in which at least one hydrogen on the alkyl is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.

The term "cycloalkyl" refers to a substituent obtained by removing a hydrogen atom from a saturated carbocycle having the number of carbon atoms designated (i.e. C₃-C₈ means three to eight carbons). Cycloalkyl refers to both a radical of a single ring saturated carbocycle, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, as well as a radical of a two or three ring bridged, fused or spiro saturated carbocycle, such as bicyclo[4.2.0]octane and decalinyl.

The term "five-membered heteroaryl" whether used alone or as part of another group, is defined herein as a ring system having five ring atoms wherein at least one ring atom, alternatively 2 ring atoms, alternatively 3 ring atoms, alternatively 4 ring atoms, is a heteroatom independently selected in each instance from, unless otherwise indicated, the group consisting of nitrogen (N), oxygen (O), and sulfur (S), and wherein the ring is partially unsaturated. In a group that has a heteroaryl substituent, unless otherwise indicated, the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon may be in a different ring from the at least one heteroatom. Where so indicated, heteroaryl groups can be substituted. If the heteroaryl substituent is substituted with a group or substituent, the group or substituent may be bound to the heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the heteroatom(s), or where the ring carbon atom may be in a different ring from the heteroatom(s). Examples of monocyclic heteroaryl rings include, but are not limited to, 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, oxazolyl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, and thiophen-4-yl.

This specification uses the terms "substituent," "radical," and "group" interchangeably.

If a group of substituents are collectively described as being optionally substituted by one or more of a list of substituents, the group may include: (1) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) substitutable substituents that are substituted by one or more of the optional substituents.

5 If a substituent is described such that it "may be substituted" or as being "optionally substituted" with up to a particular number of non-hydrogen substituents, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally
10 substituted with up to 3 non-hydrogen substituents, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen substituent. To illustrate further, if an amino nitrogen is described as being optionally substituted
15 with up to 2 non-hydrogen substituents, then the nitrogen will be optionally substituted with up to 2 non-hydrogen substituents if the amino nitrogen is a primary nitrogen, whereas the amino nitrogen will be optionally substituted with up to only 1 non-hydrogen substituent if the amino nitrogen is a secondary nitrogen.

As used herein compounds of Formula I may be referred to as a "compound(s) of the
20 invention." Such terms are also defined to include all forms of the Formula I including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites thereof. For example, the compounds of Formula I and pharmaceutically acceptable salts thereof, may exist in unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the
25 solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.

A "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. The term "active metabolite" refers to a biologically
30 active derivative of a compound that is formed when the compound is metabolized. The term "metabolized," as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes, such as, oxidation reactions) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and
35 reductive reactions while uridine diphosphate glucuronyl transferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids,

amines and free sulfhydryl groups. Further information on metabolism may be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites of the compounds disclosed herein can be identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds. Both methods are well known in the art. In some embodiments, metabolites of a compound are formed by oxidative processes and correspond to the corresponding hydroxy-containing compound. In some embodiments, a compound is metabolized to pharmacologically active metabolites.

In some embodiments, compounds described herein could be prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound. (see, for example, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401, Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).

Prodrug forms of the herein described compounds, wherein the prodrug is metabolized *in vivo* to produce a derivative as set forth herein are included within the scope of the claims. In some cases, some of the herein-described compounds may be a prodrug for another derivative or active compound.

Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. Prodrugs may be designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues. In some embodiments, the design of a prodrug increases the effective water solubility. See, e.g., Fedorak et al., *Am. J. Physiol.*, 269:G210-218 (1995); McLoed et al., *Gastroenterol.*, 106:405-413 (1994); Hochhaus et al., *Biomed. Chrom.*, 6:283-286 (1992); J. Larsen and H. Bundgaard, *Int. J. Pharmaceutics*, 37, 87 (1987); J. Larsen et al., *Int. J. Pharmaceutics*, 47, 103 (1988); Sinkula et al., *J. Pharm. Sci.*, 64:181-210 (1975); T. Higuchi and V. Stella, *Pro-drugs as Novel Delivery Systems*, Vol. 14 of the A.C.S. Symposium Series; and Edward B. Roche, *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987, all incorporated herein in their entirety.

The compounds of the invention may have asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line, a solid wedge or a dotted wedge. The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of the invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.

Stereoisomers of compounds of the invention include cis and trans isomers, optical isomers such as *R* and *S* enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.

When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the

racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.

The present invention also includes isotopically-labeled compounds, which are identical to those recited in Formula I herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl . Certain isotopically-labeled compounds of Formula (I) and Formula (II), for example those into which radioactive isotopes such as ^3H and ^{14}O are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-labeled compounds the invention may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.

The compounds of this invention may be used in the form of salts derived from inorganic or organic acids. Depending on the particular compound, a salt of the compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil. In some instances, a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.

Where a salt is intended to be administered to a patient (as opposed to, for example, being used in an *in vitro* context), the salt preferably is pharmaceutically acceptable. The term "pharmaceutically acceptable salt" refers to a salt prepared by combining a compound of Formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are non-toxic "pharmaceutically acceptable salts." Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.

Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric,

hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. Suitable organic acids generally include but are not limited to aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.

Specific examples of suitable organic acids include but are not limited to acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, algenic acid, β -hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.

Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, N,N'-benzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (C_1 - C_6) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (i.e., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (i.e., benzyl and phenethyl bromides), and others.

In one embodiment, hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

Compounds

In the following description of compounds suitable for use in the methods described herein, definitions of referred-to standard chemistry terms may be found in reference works (if not otherwise defined herein), including Carey and Sundberg "Advanced Organic Chemistry 4th Ed."


Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the ordinary skill of the art are employed. Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory
5 procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

In certain embodiments, the compounds of the invention described herein are selective for
10 ROR γ over ROR α and/or ROR β .

Generally, an inhibitor compound of ROR γ used in the methods described herein is identified or characterized in an *in vitro* assay, e.g., an acellular biochemical assay or a cellular functional assay. Such assays are useful to determine an *in vitro* IC₅₀ for said compounds. In some embodiments, the ROR γ inhibitor compound used for the methods described herein inhibits
15 ROR γ activity with an *in vitro* IC₅₀ of less than 25 μ M (e.g., less than 20 μ M, less than 10 μ M, less than 1 μ M, less than 0.5 μ M, less than 0.4 μ M, less than 0.3 μ M, less than 0.1, less than 0.08 μ M, less than 0.06 μ M, less than 0.05 μ M, less than 0.04 μ M, less than 0.03 μ M, less than less than 0.02 μ M, less than 0.01, less than 0.008 μ M, less than 0.006 μ M, less than 0.005 μ M, less than 0.004 μ M, less than 0.003 μ M, less than less than 0.002 μ M, less than 0.001, less than 0.00099
20 μ M, less than 0.00098 μ M, less than 0.00097 μ M, less than 0.00096 μ M, less than 0.00095 μ M, less than 0.00094 μ M, less than 0.00093 μ M, less than 0.00092, or less than 0.00090 μ M). In some embodiments, the ROR γ inhibitor compound is a compound described in the Exemplification.

Described herein are compounds of Formula I. Also described herein are pharmaceutically
25 acceptable salts, pharmaceutically acceptable solvates, pharmaceutically active metabolites, and pharmaceutically acceptable prodrugs of such compounds. Pharmaceutical compositions that include at least one such compound or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically active metabolite or pharmaceutically acceptable prodrug of such compound, are provided. In some embodiments, when compounds disclosed herein contain
30 an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. In certain embodiments, isomers and chemically protected forms of compounds having a structure represented by Formula I are also provided.


One aspect of the invention relates to a compound of Formula I:




I

or a pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, wherein,

5 X is phenyl or 5-membered heteroaryl, in each case optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of -CH₃, -CF₃, -

CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN;

R¹ is -CH₃ or -CH₂CH₃;


10 W is , optionally substituted with one, two, three, four or five -CH₃; and

R² is (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl, phenyl or isothiazolyl, optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₈)cycloalkyl.


15 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R¹ is -CH₃.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R¹ is -CH₂CH₃.

In certain embodiments, the present invention relates to any of the aforementioned

20 compounds, wherein W is , optionally substituted with one, two, three, four or five -CH₃.

In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein W is , optionally substituted with one, two, three, four or five -CH₃; and R¹ is -CH₃.


In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



5 In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



15 In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned




5 In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned




15 In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned




5 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is unsubstituted phenyl.


In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one, two, three, four or five substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃,



In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one substituent selected from the group consisting of with -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH,




15 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with two substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH,




20 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with three substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, -F, -Cl, -Br and -CN.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with four substituents independently selected from the


group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{OCH}_2\text{CH}_2\text{OH}$,




In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with five substituents independently selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{OCH}_2\text{CH}_2\text{OH}$,





In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with $-\text{F}$ and optionally substituted with one or two substituents independently selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OH}$,




In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$,




In certain embodiments, the present invention relates to any of the aforementioned







In certain embodiments, the present invention relates to any of the aforementioned




group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH,

-OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN.


In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein X is , , , or .



5 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is 5-membered heteroaryl optionally substituted with one, two, three, or four substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃,

-OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN.

10 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is isoxazolyl or pyrazolyl, in each case optionally substituted with one, two or three, substituents independently selected from the group consisting of -CH₃, -CF₃,

-CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN.

15 In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein X is  or . In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is (C₁-C₆)alkyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl,

20 -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is unsubstituted (C₁-C₆)alkyl. In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is unsubstituted branched (C₁-C₆)alkyl.

5 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is (C₁-C₃)alkyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

10 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is methyl optionally substituted with one, two or three substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

15 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is ethyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

20 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is n-propyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is i-propyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

25 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is methyl substituted with (C₃-C₆)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is propyl substituted with -CF₃.

30 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is ethyl substituted with (C₃-C₆)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is ethyl substituted with bicyclo[1.1.1]pentanyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R^2 is (C₃-C₁₀)cycloalkyl optionally substituted with one, two, three, four or five

substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is unsubstituted (C₃-C₁₀)cycloalkyl.

5 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is cyclopropyl optionally substituted with one, two, three or four substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

10 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is cyclobutyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

15 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is cyclopentyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

20 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is cyclohexyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is unsubstituted phenyl.

25 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

30 In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH and -CH₃.


In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is unsubstituted isothiazolyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is isothiazolyl optionally substituted with one, two, three, four or five


substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.

In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R² is isothiazolyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH and -CH₃.


In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned




5 In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned




15 In certain embodiments, the present invention relates to any of the aforementioned




In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .

In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .


5 In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .

In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .

In certain embodiments, the present invention relates to any of the aforementioned

10 compounds, wherein R^2 is .


In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .


In certain embodiments, the present invention relates to any of the aforementioned

compounds, wherein R^2 is .


In certain embodiments, the present invention relates to any of the aforementioned



In certain embodiments, the present invention relates to any of the aforementioned



5 In certain embodiments, the present invention relates to any of the aforementioned



Another embodiment of the invention is a compound selected from the group consisting of the compounds of Examples 1-35 and pharmaceutically acceptable salts thereof.

Therapeutic Applications

10 It is contemplated that the compounds of Formula I provide therapeutic benefits to subjects suffering from an immune disorder or inflammatory disorder. Accordingly, one aspect of the invention provides a method of treating a disorder selected from the group consisting of an immune disorder or inflammatory disorder. The method comprises administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof to ameliorate a symptom
15 of the disorder, wherein Formula I are as described above. In certain embodiments, the particular compound of Formula I is a compound defined by one of the embodiments described above.

In certain embodiments, the disorder is an immune disorder. In certain other embodiments, the disorder is an inflammatory disorder. In certain other embodiments, the disorder is an autoimmune disorder. In certain other embodiments, the disorder is rheumatoid arthritis,
20 psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, or epidermal hyperplasia.

In certain other embodiments, the disorder is cartilage inflammation, bone degradation,
25 arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's

Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic
5 arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodosa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal
10 hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, giant cell arteritis, nonalcoholic hepatic steatosis, or an immune disorder associated with or arising from activity of pathogenic lymphocytes.

In certain embodiments, the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

15 In certain other embodiments, the disorder is noninfectious uveitis, Behcet's disease or Vogt-Koyanagi-Harada syndrome.

Another aspect of the invention provides for the use of a compound of Formula I in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein.

20 Another aspect of the invention provides for the use of a compound of Formula I for treating a medical disorder, such a medical disorder described herein.

Further, it is contemplated that compounds of Formula I can inhibit the activity of ROR γ . Accordingly, another aspect of the invention provides a method of inhibiting the activity of ROR γ . The method comprises exposing a ROR γ to an effective amount of a compound of Formula I to
25 inhibit said ROR γ , wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compound defined by one of the embodiments described herein.

Further, it is contemplated that compounds of Formula I can reduce the amount of interleukin-17 (IL-17) in a subject. IL-17 is a cytokine that affects numerous biological functions, including inducing and mediating pro-inflammatory responses. Accordingly, another aspect of the
30 invention provides a method of reducing the amount of IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of I to reduce the amount of IL-17 in the subject, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.

In certain embodiments, the subject is a human. In certain embodiments, administering
35 the compound reduces the amount of IL-17 produced by Th-17 cells in the subject. A change in the

amount of IL-17 produced by, for example, Th-17 cells can be measured using procedures described in the literature, such as an ELISA assay or intracellular staining assay.

Further, it is contemplated that compounds of Formula I may inhibit the synthesis of IL-17 in a subject. Accordingly, another aspect of the invention provides a method of inhibiting the synthesis IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of Formula I to inhibit the synthesis IL-17 in the subject, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.

The description above describes multiple embodiments providing definitions for variables used herein. The application specifically contemplates all combinations of such variables.

Combination Therapy

Another aspect of the invention provides for combination therapy. For example, the compounds of Formula I or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as medical disorders associated with inappropriate IL-17 pathway activity. Exemplary additional therapeutic agents include, for example, (1) a TNF- α inhibitor; (2) a non-selective COX-1/COX-2 inhibitor; (3) a selective COX-2 inhibitor, such as celecoxib and rofecoxib; (4) other agents for treating inflammatory disease and autoimmune disease including, for example, methotrexate, leflunomide, sulfasalazine, azathioprine, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, hydroxychloroquine, d-penicillamine, aurothiomalate, auranofin, parenteral gold, oral gold, cyclophosphamide, Lymphostat-B, a BAFF/ APRIL inhibitor, CTLA-4-Ig, or a mimetic of CTLA-4-Ig; (5) a leukotriene biosynthesis inhibitor, such as a 5-lipoxygenase (5-LO) inhibitor, or a 5-lipoxygenase activating protein (FLAP) antagonist; (6) a LTD₄ receptor antagonist; (7) a phosphodiesterase type IV (PDE-IV) inhibitor, such as cilomilast (ariflo) or roflumilast; (8) an antihistamine H₁ receptor antagonist; (9) an α_1 - and α_2 -adrenoceptor agonist; (10) an anticholinergic agent; (11) a β -adrenoceptor agonist; (12) an insulin-like growth factor type I (IGF-1) mimetic; (13) a glucocorticoid; (14) a kinase inhibitor such as an inhibitor of a Janus Kinase (e.g., JAK 1 and/or JAK2 and/or JAK 3 and/or TYK2), p38 MAPK, Syk or IKK2; (15) a B-cell target biologic such as rituximab; (16) a selective co-stimulation modulator such as abatacept; (17) an interleukin inhibitor or interleukin receptor inhibitor, such as the IL-1 inhibitor anakinra, IL-6 inhibitor tocilizumab, and IL12/IL-23 inhibitor ustekimumab; (18) an anti-IL17 antibody, anti-IL21 antibody, or anti-IL22 antibody (19) a S1P₁ agonist, such as fingolimod; (20) an interferon, such as interferon beta 1; (21) an integrin inhibitor such as natalizumab; (22) a mTOR inhibitor such as rapamycin, cyclosporin and tacrolimus; (23) a non-steroidal antiinflammatory agent (NSAID), such as propionic acid derivatives (alminoprofen, benoxaprofen, buclocic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, piroprofen,

pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (24) a NRF2 pathway activator, such as the fumaric acid derivative, BG-12; and (25) a chemokine or chemokine receptor inhibitor, such as a CCR9 antagonist.

In certain embodiments, the additional therapeutic agent is selected from the group consisting of corticosteroids, vitamin D3, anthralin and retinoids. In certain embodiments, the additional therapeutic agent is a corticosteroid. In certain embodiments, the additional therapeutic agent is vitamin D3. In certain embodiments, the additional therapeutic agent is anthralin. In certain embodiments, the additional therapeutic agent is a retinoid.

The amount of the compounds of Formula I and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined therapeutic effect. For example, when administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. Further, for example, a compound of Formula I may be administered during a time when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or vice versa.

The doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician. In certain embodiments, the compound of Formula I and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder. In other embodiments, the compound of Formula I and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder. In certain embodiments, a compound of Formula I and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.

In certain embodiments, the compound of Formula I and the additional therapeutic agent(s) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.

Another aspect of this invention is a kit comprising a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.

Pharmaceutical Compositions and Dosing Considerations

5 Typically, a compound of the invention is administered in an amount effective to treat a condition as described herein. The compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using
10 preclinical and clinical approaches familiar to the medicinal arts. The term "therapeutically effective amount" as used herein refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.

The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term
15 applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. The term "treating" also includes adjuvant and neo-adjuvant treatment of a subject.

As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated
20 together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. The pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2)
25 parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.

30 The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.

Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as

an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.

In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally

contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one
5 or more of the above-described excipients.

Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
10 emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting
15 agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and
20 mixtures thereof.

Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and
25 which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
30

The invention also includes pharmaceutical compositions utilizing one or more of the present compounds along with one or more pharmaceutically acceptable carriers, excipients, vehicles, etc.

Topical formulations of the presently disclosed compounds may be administered topically, (intra)dermally, or transdermally to the skin or mucosa. Topical administration using such preparations encompasses all conventional methods of administration across the surface of the body and the inner linings of body passages including epithelial and mucosal tissues, including transdermal, epidermal, buccal, pulmonary, ophthalmic, intranasal, vaginal and rectal modes of administration. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, colloid, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Such topical formulations may be prepared in combination with additional pharmaceutically acceptable excipients.

In certain embodiments, a penetration enhancer may be used. Examples of penetration enhancers include, for example, saturated C10-C18 fatty alcohols (such as decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol and stearyl alcohol), cis-unsaturated C10-C18 fatty alcohols (such as oleyl alcohol, linoleyl alcohol, γ -linolenyl alcohol and linolenyl alcohol), C10-C18 fatty acids (which when saturated may include capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid), cis-unsaturated fatty acids (such as palmitoleic acid (cis-9-hexadecenoic acid), oleic acid (cis-9-octadecenoic acid), cis-vaccenic acid (cis-11-octadecenoic acid), linoleic acid (cis-9,12-octadecadienoic acid), γ -linolenic acid (cis-6,9,12-octadecatrienoic acid), linolenic acid (cis-9,12,15-octadecatrienoic acid) and arachidonic acid (cis-5,8,11,14-eicosatetraenoic acid)). In certain embodiments, the penetration enhancers may be used amounts ranging from about 0.1 to about 5% (w/v).

In certain embodiments, topical formulations which contain one or more compounds of the invention in therapeutically effective amounts that may be given in daily or twice daily doses to patients in need.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Other excipients which enhance the stability of the formulations include aldehyde scavengers, such as glycerine and propylene glycol, and antioxidants, such as butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), propyl gallate, ascorbic acid (Vitamin C), polyphenols, tocopherols (Vitamin E), and their derivatives.

Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

5 Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

10 Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aural administration may be in the form of drops of a micronised suspension or solution in isotonic, pH-
15 adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (i.e., absorbable gel sponges, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or
20 methylcellulose, or a heteropolysaccharide polymer, for example, gelatin gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray
25 container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone; as a mixture, for example, in a dry blend with lactose; or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol
30 spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

Pharmaceutical compositions of this invention suitable for parenteral administration
35 comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions,

suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

5 Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of
10 the required particle size in the case of dispersions, and by the use of surfactants.

 These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to
15 include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

 In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of
20 a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

 Injectable depot forms are made by forming microencapsule matrices of the subject
25 compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

30 When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.

 The preparations of the present invention may be given orally, parenterally, topically, or
35 rectally. They are of course given in forms suitable for each administration route. For example,

they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.

Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the

pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.

When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone.

If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments, preferred dosing is one administration per day.

The invention further provides a unit dosage form (such as a tablet or capsule) comprising a compound of Formula I or a specific compound described herein, or pharmaceutically acceptable salts thereof, in a therapeutically effective amount for the treatment of an immune or inflammatory disorder, such as one of the particular immune disorders or inflammatory disorders described herein.

General Synthetic Schemes and Procedures

The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art (such as those methods disclosed in standard reference books such as the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. I-VI (published by Wiley-Interscience)). Preferred methods include, but are not limited to, those described below.

During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.


Compounds of Formula I or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.

5 It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of representation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended claims. The schemes are representative of methods useful in synthesizing the compounds of the
10 present invention. They are not to constrain the scope of the invention in any way.

Compounds of Formula I may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures. Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry. Such methods include but are not limited to
15 preferential crystallization of diastereomeric salts (e.g. tartrate or camphor sulfonate), covalent derivatization by a chiral, non-racemic reagent followed by separation of the resulting diastereomers by common methods (e.g. crystallization, chromatographic separation, or distillation) and chemical reversion to scalemic compound, Simulated Moving Bed technology, or high/medium-pressure liquid chromatography or supercritical fluid chromatography employing a
20 chiral stationary phase. These techniques may be performed on the final compounds of the invention or on any intermediates to compounds of the invention which bear a stereogenic center. Also, to facilitate separation by any of the methods described above, the compounds of the invention or any intermediates to the compounds of the invention which bear a stereogenic center may be transiently reacted with an achiral reagent, separated, and then reverted to scalemic
25 compound by standard synthetic techniques.


Compounds of Formula A-6 can be prepared as described in **Scheme A**. Aryl halides A-1 can be converted to boronates of Formula A-2. Boronates A-2 can be coupled with vinyl triflate B-3 (prepared as described in **Scheme B**) to afford compounds of the Formula A-3. Subsequent reduction of the nitro group and the olefin concomitantly furnished compounds of Formula A-4.
30 The resulting amine of compounds of Formula A-4 can be transformed to the corresponding sulfonamides by the reaction with sulfonyl chlorides in the presence of base to afford compounds of Formula A-5. The Boc group within compounds of Formula A-5 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula A-6.

SCHEME A



Compounds of formula B-3 can be prepared as exemplified by the synthetic route described in **Scheme B**. Hydrogenolysis of B-1 in the presence of Boc anhydride removed the benzyl group from the piperidine nitrogen and this was followed by immediate carbamate formation *in situ* to form carbamate B-2. Next, treatment with a strong base such as lithium hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with *N*-phenyl triflamide to form vinyl triflate B-3.

SCHEME B




Compounds of Formula C-5 can be prepared as in the route described in **Scheme C**. Iodide C-1 was coupled with Boc-protected piperidine boronate C-6 through the use of conventional Suzuki conditions employing palladium tetrakis(triphenylphosphine). Next, hydrogenation conditions could be used to convert nitroolefin C-2 to the corresponding aniline C-3.

This aniline could be substituted with various sulfonyl chlorides to provide structures of the formula C-4. The Boc group within C-4 could be removed through use of acid, and subsequently the piperidine nitrogen coupled with the an appropriate acid chloride or carboxylic acid to furnish compounds of Formula C-5.

5


SCHEME C



Compounds of Formula D-5 can be prepared as exemplified by the synthetic route described in **Scheme D**. The boronate A-2 prepared as described in Scheme A was coupled to Boc protected E-2 prepared as described in Scheme E through the use of conventional Suzuki


10 conditions. Next hydrogenation could be used to convert nitroolefin D-2 to the corresponding aniline D-3. The resulting aniline could be substituted with various sulfonyl chlorides to provide compounds of Formula D-4. The Boc group within C-4 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula D-5.

SCHEME D




Compounds of formula E-2 can be prepared as exemplified by the synthetic route described in **Scheme E**. Treatment of piperidone E-1 with a strong base such as lithium
 5 hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with *N*-phenyl triflamide to form vinyl triflate E-2.

SCHEME E




Compounds of Formula F-5 can be prepared as exemplified by the synthetic route
 10 described in **Scheme F**. The boronate A-2 prepared as described in Scheme A is coupled to Boc protected G-2 through the use of conventional Suzuki conditions. Next hydrogenation could be used to convert nitroolefin F-2 to the corresponding aniline F-3. The resulting aniline could be substituted with various sulfonyl chlorides to provide compounds of the Formula F-4. The Boc
 15 group within F-4 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula F-5.

SCHEME F



Compounds of formula G-2 can be prepared as exemplified by the synthetic route described in **Scheme G**. Treatment of piperidone G-1 with a strong base such as lithium hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with *N*-phenyl triflamide to form vinyl triflate G-2.


SCHEME G



Carboxylic acids of the Formula R^2CO_2H employed in **Scheme A**, **C**, **D**, and **F** may be commercially available, prepared by procedures described in the literature, or prepared as described in **Scheme F**. (R)-2,3,3-Trimethylbutanoic acid and (S)-2,3,3-trimethylbutanoic acid may be prepared as described by Kido, M. et al Tetrahedron: Asym. 2007, 18, 1934-1947; and thietane acid (see WO2013/7582, which is hereby incorporated by reference for the preparation of thietane acid). Specific examples of carboxylic acids that may be prepared by **Scheme F** include (R)-2-cyclopentylpropanoic acid, and (S)-2-cyclopentylpropanoic acid. Specific examples of R_2CO_2H according to the Formula F-4 can be prepared from acids F-1 where R may be alkyl, cycloalkyl or

aryl which are reacted with an optically active chiral oxazolidinone (e.g. (R)-benzyl oxazolidinone, (R)-4-Isopropyl-2-oxazolidinone) to provide compounds of the Formula F-2. Base mediated alkylation and subsequent removal of the oxazolidinone auxiliary furnishes acids of the Formula F-4 in high optical purity. By employing a chiral oxazolidinone of a different absolute configuration (e.g. (S)-benzyl oxazolidinone, (S)-4-Isopropyl-2-oxazolidinone), chiral acids F-4 of both configurations can be obtained.

SCHEME F



EXEMPLIFICATION

The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention. The following illustrates the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.

Experiments were generally carried out under inert atmosphere (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic resonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed. Coupling constants (J values) are reported in Hertz.

Chiral purity of scalemic compounds was determined by chiral SFC (super-critical fluid chromatography) employing one of the following conditions: HPLC **Method A**: XBridge C18, 2.1x50 mm, 5 μ m, CH₃CN/H₂O (0.0375% TFA), 10-100%, 0.8 mL/min, 4min; and HPLC **Method B**: XBridge C18, 2.1x50 mm, 5 μ m, CH₃CN/H₂O (0.0375% TFA), 1-100%, 0.8 mL/min, 4min. **Method C**: Ultimate XB-C18, 3 μ m, 3.0x50mm, CH₃CN/H₂O (0.1% TFA), 1-5%, 1.2 mL/min, 10 min. **Method D**: Xtimate C18, 3 μ m, 5.0x50mm, CH₃CN/H₂O (0.1% TFA), 1-100%, 1.2 mL/min, 10

min. **Method E:** Ultimate XB-C18, 3 μ m, 3.0x50mm, CH₃CN/H₂O (0.1% TFA), 1-100%, 1.2 mL/min, 10 min.


For syntheses referencing procedures in other Examples, reaction conditions (length of reaction and temperature) may vary. In general, reactions were followed by thin layer chromatography or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluants/gradients were chosen to provide appropriate R_f's or retention times (RetT).

The chemical names for the compounds of the invention described below were generated using CambridgeSoft's ChemBioDraw Ultra version 13.0.2 (CambridgeSoft Corp., Cambridge Mass.).

The following abbreviations are used herein: DCM: dichloromethane; DEA: diethylamine; DIPEA: diisopropylethylamine; DME: 1,2-dimethoxyethane; DMF: dimethylformamide; EtOAc: ethyl acetate; EtOH: ethanol; HATU: 1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; MeOH: methanol; MTBE: methyl t-butyl ether; PE: petroleum ether; TEA: triethylamine; and THF: tetrahydrofuran.

Example 1

Preparation of 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methyl-1-((R)-2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide



Step 1: 3-Bromo-1-methyl-5-nitro-1H-indole. To a solution 3-bromo-5-nitro-1H-indole (5.5 g, 20.6 mmol) in THF (50mL) at 0 °C was added NaH (1.9 g, 41.3 mmol, 60% w/w in mineral oil). The mixture was stirred for 15 min and methyl iodide (6.4 mL, 103.3 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 16 h. After completion, the reaction mixture was cooled, quenched with addition of ice-cooled water and extracted using EtOAc. The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated to obtain a crude product which was purified by triturating with diethyl ether to afford the title compound (5 g, 86%). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 2.4 Hz, 1H), 8.17 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 1H), 7.25 (s, 1H), 3.87 (s, 3H).

Step 2: 1-Methyl-5-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole. A solution of 3-bromo-1-methyl-5-nitro-1*H*-indole (3 g, 11.7 mmol) in dioxane (100 mL) was degassed using nitrogen for 10 min. K₂CO₃ (4.8 g, 35.1 mmol), S-Phos (480 mg, 1.17 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (4.46 g, 17.5 mmol) and Pd₂(dba)₃ (533 mg, 0.58 mmol) were added, degassed with nitrogen for another 10 min and heated at 60 °C for 5 h. After completion, the reaction mixture was cooled to room temperature, quenched with the addition of saturated NH₄Cl solution and extracted using EtOAc. The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated to obtain a crude product which was purified by flash silica gel column chromatography (5-7% EtOAc in hexane) to afford the title compound (1 g, 28%). ¹H NMR (400 MHz, CDCl₃) δ 8.93 (d, *J* = 2.0 Hz, 1H), 8.14 (dd, *J* = 9.2, 2.0 Hz, 1H), 7.64 (s, 1H), 7.33 (d, *J* = 9.2 Hz, 1H), 3.86 (s, 3H), 1.38 (s, 12H); LCMS: *m/e* 303 [M+H]⁺.

Step 3: *tert*-Butyl 3-methyl-4-oxopiperidine-1-carboxylate. To a solution of 1-benzyl-3-methylpiperidin-4-one (6 g, 29.5 mmol) in ethanol was added Boc-anhydride (8 g, 36.9 mmol), Pd(OH)₂ (2.4 g, 40% wt of ketone) and the reaction mixture was stirred under hydrogen atmosphere (100 psi) in autoclave for 6 h at room temperature. After completion, the reaction mixture was concentrated in *vacuo* to obtain a crude residue which was purified by silica gel column chromatography (10-15% EtOAc in hexane) to afford the title compound (8.8 g, 78%). ¹H NMR (400 MHz, CDCl₃): δ 4.20-4.16 (m, 2H), 3.29-3.22 (m, 1H), 2.85 (br.s, 1H), 2.57-2.38 (m, 3H), 1.49 (s, 9H), 1.04 (d, *J* = 6.4 Hz, 3H); LCMS: *m/e* 235 [M+Na]⁺.

Step 4: *tert*-Butyl 3-methyl-4-(((trifluoromethyl) sulfonyl)oxy)-3,6-dihydropyridine-1(2*H*)-carboxylate. To a solution of *tert*-Butyl 3-methyl-4-oxopiperidine-1-carboxylate (7 g, 32.8 mmol) in THF (70 mL) was added a solution of NaHMDS (66 mL, 65.7 mmol, 1M in THF) dropwise at -78 °C, stirred for 1.5 h at the same temperature, 1,1,1-trifluoro-*N*-phenyl-*N*-(((trifluoromethyl)sulfonyl)methanesulfonamide) (23.4 g, 65.7 mmol) was added, the reaction mixture was warmed to room temperature and stirred for 16 h. After completion, the reaction mixture was quenched with addition of ice-cooled water and extracted using EtOAc. The combined organic layer was washed with 10% citric acid followed by 2N NaOH solution, dried over anhydrous Na₂SO₄, filtered and concentrated to obtain a crude product which was purified by silica gel column chromatography (3-5% EtOAc in hexane) to afford the title compound (8.8 g, 78%). ¹H NMR (400 MHz, CDCl₃): δ 5.73-5.72 (m, 1H), 4.12-3.96 (m, 2H), 3.61-3.40 (m, 2H), 2.62-2.61 (m, 1H), 1.47 (s, 9H), 1.14 (d, *J* = 6.8 Hz, 3H).

Step 5: *tert*-butyl 3-methyl-4-(1-methyl-5-nitro-1*H*-indol-3-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate. A solution of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole (1 g, 3.32 mmol) in dioxane: water (40 mL: 5 mL) was degassed using nitrogen for 10 min., *tert*-butyl 5-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2*H*)-carboxylate (1.4g,

4.05 mmol), K_3PO_4 (1.5g, 7.1 mmol), tetrakis (triphenyl phosphine) palladium(0) (375 mg, 0.32 mmol) were added, degassed for another 10 min. and the reaction mixture was heated at 90 °C for 5h. After completion, the reaction mixture was cooled to room temperature, diluted with water and extracted using EtOAc. The combined organic layer was dried over anhydrous Na_2SO_4 ,
5 filtered and concentrated to obtain a crude product which was purified by flash silica gel column chromatography (1% MeOH in DCM) to afford a pure title compound (1 g, 82%). 1H NMR (400 MHz, $CDCl_3$): δ 8.75 (br.s, 1H), 8.14 (dd, J = 8.8, 2.0 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.01 (br.s, 1H), 7.26-7.25 (m, 1H), 4.52-4.35 (m, 1H), 4.05-3.84 (m, 5H), 3.30-3.29 (m, 1H), 2.78-2.75 (m, 1H), 1.51 (s, 9H), 1.09 (d, J = 6.8 Hz, 3H); LCMS: m/e 435.4 $[M+Na+CH_3CN]^+$.

10 Step 6: *tert*-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate. To a solution of *tert*-butyl 5-methyl-4-(1-methyl-5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1 g, 2.6 mmol) in EtOH (25 mL) were added $Pd(OH)_2$ (1 g, 100% w/w), ammonium formate (1.7 g, 26.9 mmol) and the reaction mixture was heated at 80 °C for 4h. After completion, the reaction mixture was cooled to room temperature, filtered through celite® and washed with
15 EtOH. The filtrate was concentrated to afford the title compound (900 mg, 97%) which was used in the next step without further purification. 1H NMR (400 MHz, $CDCl_3$): δ 7.09 (d, J = 8.4 Hz, 1H), 6.92-6.91 (m, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.67 (s, 1H), 4.29-3.96 (m, 2H), 3.76-3.68 (m, 4H), 3.16-2.88 (m, 3H), 2.22-2.19 (m, 1H), 1.98-1.96 (m, 1H), 1.66-1.63 (m, 2H), 1.47 (s, 9H), 0.69 (d, J = 6.4 Hz, 3H); LCMS: m/e 344.35 $[M+H]^+$.

20 Step 7: *tert*-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate. To a solution of *tert*-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate (900 mg, 2.62 mmol) in DCM (25 mL) was added pyridine (0.32 mL, 3.93 mmol), followed by 4-fluorobenzenesulfonyl chloride (613 mg, 3.14 mmol) solution in DCM (25 mL) dropwise at 0-5 °C and the resulting reaction mixture was stirred at 0-5 °C for 30
25 min. After completion, the reaction mixture was basified with 10% aqueous $NaHCO_3$ solution and extracted using DCM. The combined organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated to obtain the crude compound which was purified by silica gel column chromatography (1-2% MeOH in DCM) to afford the title compound (1 g, 68%). 1H NMR (400 MHz, $CDCl_3$): δ 7.66 (d, J = 5.6 Hz, 1H), 7.65 (d, J = 5.6 Hz, 1H), 7.20 (br.s, 1H), 7.12 (d, J = 8.4 Hz,
30 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.75 (s, 1H), 6.37 (s, 1H), 4.29-3.95 (m, 2H), 3.71 (s, 3H), 3.12-2.85 (m, 3H), 2.02-1.93 (m, 2H), 1.65-1.58 (m, 1H), 1.48 (s, 9H), 0.62 (d, J = 6.4 Hz, 3H).

Step 8: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. Racemic *tert*-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate (1.1 g) was separated by chiral SFC (Column: Lux
35 Cellulose-4, 250 x 21.2 mm, 5 μ m, 80% CO_2 /20% MeOH + 0.2% NH_4^+ , 80 mL/min) to give two


major peaks for which absolute stereochemistry were arbitrarily assigned. The first eluting isomer (R_t = 8.89 min) was arbitrarily assigned as tert-butyl (3S,4S)-4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate. The second eluting isomer (R_t = 9.78 min) was arbitrarily assigned tert-butyl (3R,4R)-4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate. ^1H NMR (400 MHz, CDCl_3): δ 7.66 (d, J = 5.6 Hz, 1H), 7.65 (d, J = 5.6 Hz, 1H), 7.20 (br.s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.75 (s, 1H), 6.37 (s, 1H), 4.29-3.95 (m, 2H), 3.71 (s, 3H), 3.12-2.85 (m, 3H), 2.02-1.93 (m, 2H), 1.65-1.58 (m, 1H), 1.48 (s, 9H), 0.62 (d, J = 6.4 Hz, 3H).

Step 9: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. To a solution of (3R,4R)-tert-butyl 4-(5-(4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-3-methylpiperidine-1-carboxylate (273 mg, 0.544 mmol) in DCM (10.9 mL, 0.05 mmol) was added 4M HCl in dioxane (2.04 mL, 8.16 mmol) at room temperature. The resulting mixture was allowed to stir for 90 min.. The solvent was removed in vacuo to afford the crude product as a black solid, which was used without further purification (238 mg, >99%). ^1H NMR (400 MHz, MeOD) δ 7.66 (dd, 2 H, J =8.8, 5.3 Hz), 7.35 - 7.07 (m, 4 H), 7.05 (s, 1 H), 6.82 (d, 1 H, J =8.6 Hz), 3.74 (s, 3 H), 3.48 - 3.25 (m, 7 H), 2.45-2.33 (m, 1 H), 2.26-2.11 (m, 1 H), 2.07-1.96 (m, 1 H), 0.79 (d, 3 H, J =7.4 Hz).

Step 10: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methyl-1-((R)-2,3,3-trimethylbutanoyl)-piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. To a solution of (R)-2,3,3-trimethylbutanoic acid (152.0 mg, 0.347 mmol) in DMF (3.47 mL) was added successively 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide (152 mg, 0.347 mmol), HATU (160 mg, 0.416 mmol) and DIPEA (453 mg, 3.47 mmol). The resulting yellow solution was allowed to stir at room temperature. LC/MS showed that the reaction was complete after 1 h. The reaction was quenched with sat. NaHCO_3 , extracted with EtOAc (3x100 mL), washed with brine, dried over MgSO_4 , filtered and. The crude product was purified silica gel column chromatography (0 to 100% EtOAc in heptane) to afford the title compound (172 mg, 97%) as a white fluffy powder consisting of a mixture of rotamers (approximately 1.5:1.0 ratio). ^1H NMR (400 MHz, CDCl_3) δ 7.65 (dd, J =8.6, 5.1 Hz, 2H), 7.18 - 7.11 (m, 4H), 7.08 - 6.94 (m, 2H), 6.92 - 6.77 (m, 1H), 6.77 - 6.66 (m, 1H), 6.55 - 6.42 (m, 1H), 4.65 - 4.53 (m, 1H) 4.21 - 4.09 (m, 0.6H), 3.83-3.80 (m, 0.4 H), 3.37-3.34 (m, 0.4H), 3.28 - 3.08 (m, 1.6H), 3.00 - 2.70 (m, 1.9H), 2.59 - 2.52 (m, 0.4 H), 2.10 (br. s., 1H), 2.00 - 1.80 (m, 1H), 1.76 - 1.70 (m, 1H), 1.58 (s, 0.9H), 1.36 - 1.17 (m, 8.3H), 1.17 - 1.04 (m, 3.1H), 1.04 - 0.91 (m, 8.6H), 0.66 (d, J =7.0 Hz, 1.3H), 0.58 (d, J =7.0 Hz, 1.7H) ppm.

Example 2

Preparation of N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide



Step 1: (R)-3-(2-cyclopentylacetyl)-4-isopropylloxazolidin-2-one. To a solution of (R)-4-isopropylloxazolidin-2-one (2.0 g, 10 mmol) in THF (55 mL) at -78 °C was added dropwise *n*-BuLi (2.5 M in hexanes, 4.92 mL, 12.3 mmol). The resulting solution was allowed to stir at the same temperature for 1 h, then cyclopentyl acetyl chloride (1.86 g, 12.3 mmol) was added. The reaction turned pale yellow rapidly and was allowed to stir at -78 °C for 1 h. The reaction was quenched with sat. NaHCO₃ solution, extracted with EtOAc, dried over Na₂SO₄, filtered and concentrated to afford the title compound (3.20 g, 99%) as a pale yellow oil that solidified on standing. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.28 (m, 3H), 7.26–7.16 (m, 2H), 4.74–4.64 (m, 1H), 4.24–4.12 (m, 2H), 3.32 (dd, J=13, 3 Hz, 1H), 3.04 (dd, J=17, 7 Hz, 1H), 2.92 (dd, J=17, 7 Hz, 1H), 2.77 (dd, J=14, 10 Hz, 1H), 2.41–2.28 (m, 1H), 1.95–1.84 (m, 2H), 1.72–1.56 (m, 4H), 1.30–1.15 (m, 2H).

Step 2: (R)-3-((R)-2-cyclopentylpropanoyl)-4-isopropylloxazolidin-2-one. To a colorless solution of (R)-3-(2-cyclopentylacetyl)-4-isopropylloxazolidin-2-one (3250 mg, 11.34 mmol) in THF (50 mL) at -78 °C was added dropwise LDA (2.0 M, 6.50 mL, 13.0 mmol). The resulting yellow solution was allowed to stir at the same temperature for 1 h. MeI (3.55 mL, 56.6 mmol) was added and the reaction was allowed to warm to 0 °C over 1 h and allowed to stir at 0 °C for 3 h. The reaction was quenched with sat. NH₄Cl and extracted with EtOAc. The combined organic extracts were washed with sat. NaHCO₃ and brine, dried over magnesium sulfate, filtered and concentrated in vacuo to afford a white solid. The crude product was purified by silica gel column chromatography twice (EtOAc:Heptane, 5:95–60:40 then 5:95–50:50). The product was recrystallized from *n*-heptane to provide the title compound (680 mg, 20%) as colorless crystalline needles. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.17 (m, 5H), 4.69 (ddt, J=10, 7, 3 Hz, 1H), 4.25–4.11 (m, 2H), 3.63 (dg, J=9, 7 Hz, 1H), 3.28 (dd, J=14, 3 Hz, 1H), 2.78 (dd, J=13, 9 Hz, 1H), 2.21–2.08 (m, 1H), 1.90–1.73 (m, 2H), 1.71–1.48 (m, 4H), 1.30–1.17 (m, 4H), 1.11 (ddd, J=12.0, 5.0, 4.0 Hz, 1H).

Step 3: (R)-2-cyclopentylpropanoic acid. To a solution of (R)-3-((R)-2-cyclopentylpropanoyl)-4-isopropylloxazolidin-2-one (680 mg, 2.26 mmol) in THF/H₂O (v/v = 1/1, 12 mL) at room temperature was added LiOH·H₂O (142 mg, 3.38 mmol) followed by H₂O₂ (237 mL, 4.17 mmol, 50 wt%). The resulting solution was allowed to stir at room temperature overnight. The



reaction was quenched with 1.0 M KHSO₄ (8 mL) and extracted with EtOAc (3x). The combined organic extracts were washed with brine and dried over Na₂SO₄, filtered and concentrated. The crude product was purified by silica gel column chromatography (EtOAc:Heptane, 7:93–50:50) to afford the title compound (285 mg, 89%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 2.29 (dq, J=9, 7 Hz, 1H), 2.07–1.95 (m, 1H), 1.87–1.76 (m, 2H), 1.69–1.51 (m, 4H), 1.31–1.24 (m, 1H), 1.24–1.15 (m, 4H).



Step 4: N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. To a flask charged with 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide (prepared as described in Step 9 of Example 1, 33 mg, 0.075 mmol), (R)-2-cyclopentylpropanoic acid (12.9 mg, 0.090 mmol), HATU (37.4 mg, 0.090 mmol), DIPEA (98.4 mg, 0.753 mmol) was added DMF (1 mL). The mixture was allowed to stir for 2 h then the reaction was added to aq NaHCO₃ and extracted three times with EtOAc. The combined organic layers were concentrated to give the titled compound (11.6 mg, 90%) as a white solid: LCMS *m/z* [M + H]⁺: 526.1; (1:1.4 mixture of rotamers) ¹H NMR (400 MHz, CDCl₃) δ 7.68–7.65 (2 H, m), 7.25 (s, 0.66 H), 7.20 (s, 0.44H), 7.11 (d, *J*=8.6 Hz, 1 H), 7.07–6.98 (m, 2 H), 6.88 (d, *J*=8.6 Hz, 0.40 H), 6.81 (d, *J*=8.6 Hz, 0.60 H), 6.77–6.66 (m, 1.40 H), 6.61 (s, 0.60 H), 4.75 (d, *J*=13.3 Hz, 0.60 H), 4.50 (d, *J*=13.3 Hz, 0.40 H) 3.82 (d, *J*=13.3 Hz, 0.60 H), 3.70 (s, 3 H), 3.34 (d, *J*=13.3 Hz, 1 H), 3.26–3.11 (m, 1.60 H), 2.96 (m, 0.40 H), 2.77–2.65 (m, 0.60 H), 2.61–2.58 (m, 0.40 H), 2.50–2.38 (m, 0.60 H), 2.29–2.05 (m, 2.10 H), 1.99–1.42 (m, 9.4 H), 1.33–0.90 (m, 10.6 H), 0.68 - 0.52 (m, 3.10 H)



Examples 3-5 and 32-35


The following Examples 3-5 and 32-35 were prepared analogous to Example 1 employing the appropriate sulfonyl chloride in step 7 and the appropriate carboxylic acid coupling reagent in step 10. However, chiral separation was conducted on the final product. Separation conditions:

Method AA: Luxe Cellulose-4, 250x21.2 mm, 5 μm, 40% EtOH/CO₂, 80.0 mL/min; **Method AB:** ChiralTech IC, 250x21.2 mm, 5 μm, 60-40% (3:1) EtOAc-MeOH/CO₂, 80.0 mL/min. **Method AC:** ChiralPak AD-3, 50 x 4 mm, 3 μm, EtOH (0.05% DEA)/CO₂, 4 mL/min. **Method AD:** ChiralPak AS-H, 150 x 4 mm, 5 μm, EtOH (0.05% DEA)/CO₂, 3 mL/min. **Method AE:** ChiralPak AD-3, 50 x 4.6 mm, 3 μm, EtOH (0.05% DEA)/CO₂, 4 mL/min. **Method AF:** ChiralPak AS-H, 150 x 4.6 mm, 5 μm, EtOH (0.05% DEA)/CO₂, 3 mL/min.

Example	Structure	Name/Characterization
3	 <p>stereochemistry arbitrarily assigned</p>	<p>N-(3-((3R,4R)-1-(cyclopentanecarbonyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. Separation method AA (first eluting isomer, 8.58 min); LCMS: m/e 498.60 $[M+H]^+$. 1H NMR (400 MHz, DMSO-d_6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J = 9.2 Hz, 1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J = 13.2 Hz, 0.5H), 4.28 (d, J = 12.4 Hz, 0.5H), 4.03 (d, J = 12.4 Hz, 0.5H), 3.84 (d, J = 13.2 Hz, 0.5H), 3.67 (s, 3H), 3.37 (d, J = 10.8 Hz, 0.5H), 3.21-2.75 (m, 4H), 1.97-1.55 (m, 11H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J = 6.8 Hz, 1.5H)</p>
4	 <p>stereochemistry arbitrarily assigned</p>	<p>N-(3-((3S,4S)-1-(cyclopentanecarbonyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. Separation method AA (second eluting isomer, 9.31 min); LCMS: m/e 498.60 $[M+H]^+$. 1H NMR (400 MHz, DMSO-d_6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J = 9.2 Hz, 1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J = 13.2 Hz, 0.5H), 4.28 (d, J = 12.4 Hz, 0.5H), 4.03 (d, J = 12.4 Hz, 0.5H), 3.84 (d, J = 13.2 Hz, 0.5H), 3.67 (s, 3H), 3.37 (d, J = 10.8 Hz, 0.5H), 3.21-2.75 (m, 4H), 1.97-1.55 (m, 11H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J = 6.8 Hz, 1.5H); LCMS: m/e 498.60 $[M+H]^+$. 1H NMR (400 MHz, DMSO-d_6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J = 9.2 Hz, 1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J = 13.2 Hz, 0.5H), 4.28 (d, J = 12.4 Hz, 0.5H), 4.03 (d, J = 12.4 Hz, 0.5H), 3.84 (d, J = 13.2 Hz, 0.5H), 3.67</p>


Example	Structure	Name/Characterization
		(s, 3H), 3.37 (d, J = 10.8 Hz, 0.5H), 3.21-2.75 (m, 4H), 1.97-1.55 (m, 11H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J = 6.8 Hz, 1.5H);
5	 <p>stereochemistry arbitrarily assigned</p>	4-fluoro-N-(3-((3R,4R)-1-isobutyryl-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide. Separation method AB (first eluting isomer, 9.33 min); ^1H NMR (400 MHz, CDCl_3) δ ppm 7.68 (dd, J =8.2, 5.1 Hz, 1 H), 7.23 (br. s., 1 H), 7.15 (d, J =8.6 Hz, 1 H), 7.07 (t, J =8.4 Hz, 1 H), 6.73-6.91 (m, 1 H), 6.40 (d, J =9.4 Hz, 1 H), 4.44-4.84 (m, 1 H), 3.78-4.10 (m, 1 H), 3.15-3.46 (m, 2 H), 2.68-3.03 (m, 2 H), 2.06-2.20 (m, 1 H), 1.66-2.04 (m, 2 H), 1.09-1.24 (m, 4 H), 0.55-0.68 (m, 2 H)
32	 <p>stereochemistry arbitrarily assigned</p>	N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide. Separation method AC (second eluting isomer, 2.05 min); ^1H NMR (400 MHz, CD_3OD) δ ppm 7.28-7.22 (m, 2H), 6.97 (s, 1H), 6.89-6.87 (m, 1H), 4.65-4.53 (m, 1H), 4.04-4.00 (m, 1H), 3.74 (s, 3H), 3.62 (s, 3H), 3.49-3.47 (m, 1H), 3.33-3.26 (m, 1H), 3.05-3.03 (m, 1H), 2.83-2.80 (m, 1H), 2.65-2.63 (m, 1H), 2.24-1.57 (m, 16H), 1.21-1.11 (m, 5H), 0.68-0.59 (m, 3H); LCMS: m/e 540.2 [$\text{M} + \text{H}^+$].

Example	Structure	Name/Characterization
33	 <p data-bbox="343 795 758 824">stereochemistry arbitrarily assigned</p>	<p data-bbox="805 365 1391 891">N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-2-ethoxybenzenesulfonamide. Separation method AD (second eluting isomer, 4.93 min); ¹H NMR (400 MHz, CD₃OD) δ ppm 7.65-7.63 (m, 1H), 7.47-7.28 (m, 1H), 7.23-6.86 (m, 6H), 4.67-4.51 (m, 1H), 4.33-4.28 (m, 3H), 3.65 (s, 3H), 3.33-3.02 (m, 4H), 2.78-2.55 (m, 2H), 2.15-1.52 (m, 14H), 1.20-1.11 (m, 5H), 0.61-0.48 (m, 3H); LCMS: <i>m/e</i> 552.2 [M + H⁺].</p>
34	 <p data-bbox="343 1377 758 1406">stereochemistry arbitrarily assigned</p>	<p data-bbox="805 927 1391 1496">N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-2-fluorobenzenesulfonamide. Separation method AD (second eluting isomer, 2.36 min); ¹H NMR (400 MHz, CD₃OD) δ ppm 7.66-7.65 (m, 1H), 7.57-7.55 (m, 1H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 2H), 6.96-6.90 (m, 2H), 4.67-4.51 (m, 1H), 4.33-4.28 (m, 3H), 3.65 (s, 3H), 3.33-3.02 (m, 4H), 2.78-2.55 (m, 2H), 2.15-1.52 (m, 10H), 1.20-1.11 (m, 5H), 0.63-0.51 (m, 3H); LCMS: <i>m/e</i> 526.1 [M + H⁺].</p>

Example	Structure	Name/Characterization
35	 <p>stereochemistry arbitrarily assigned</p>	<p>N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-2-fluoro-5-methylbenzenesulfonamide.</p> <p>Separation method AD (second eluting isomer, 4.84 min); ¹H NMR (400 MHz, CD₃OD) δ ppm 7.66-7.65 (m, 1H), 7.57-7.55 (m, 1H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 2H), 6.96-6.90 (m, 2H), 4.67-4.51 (m, 1H), 4.33-4.28 (m, 3H), 3.65 (s, 3H), 3.33-3.02 (m, 4H), 2.78-2.55 (m, 2H), 2.15-1.52 (m, 13H), 1.20-1.11 (m, 5H), 0.63-0.51 (m, 3H); LCMS: <i>m/e</i> 540.1 [M + H⁺].</p>

Example 6

Preparation of 4-fluoro-N-(3-(1-(isothiazole-5-carbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide



5

Step 1: *tert*-butyl 4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate. A mixture of 3-iodo-1-methyl-5-nitro-1H-indole (10.0 g, 33.1 mmol), *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (13.3 g, 43.0 mmol), K₃PO₄ (21.1 g, 99.3 mmol) in dioxane (200 mL) and water (20 mL) was degassed and purged with nitrogen three times. Pd(PPh₃)₄ (3.06 g, 2.65 mmol) was then added under a nitrogen atmosphere. The mixture was degassed and purged with N₂ three times. The mixture was heated to 60 °C and stirred at this temperature for 14 h. The solvent was removed under reduced pressure and the residue was partitioned with EtOAc (200 mL) and water (150 mL). The aqueous layer was extracted with EtOAc (150 mLx2), the organic layers were combined, washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The crude product was purified by silica gel column chromatography (10-50% EtOAc in PE) to give the title compound (8.05 g, 68.0 %) as an orange

solid. ^1H NMR (400 MHz, CDCl_3): δ 8.82 (s, 1H), 8.17-8.15 (m, 1H), 7.37-7.32 (m, 1H), 7.16 (s, 1H), 6.18 (s, 1H), 4.17 (s, br, 2H), 3.84 (s, 3H), 3.68 (s, br, 2H), 2.55 (s, br, 2H), 1.52 (s, 9H); LCMS: m/e 380.0 $[\text{M}+\text{Na}]^+$.

Step 2: tert-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate. To a dry hydrogenation bottle was added dry $\text{Pd}(\text{OH})_2/\text{C}$ (1600 mg) under an Ar atmosphere, followed by a solution of tert-butyl 4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (8050 mg, 22.5 mmol) in EtOH (500 mL) and DCM (50 mL). The mixture was degassed and refilled with H_2 3 times, then the mixture was stirred under a hydrogen atmosphere (50 Psi) at 50 °C for 48 hours. The mixture was filtered through a pad of Celite®, and the filtrate was concentrated to give the crude product (7700 mg, 100%) as a purple solid, which wasn't hydrogenated completely according to proton NMR. The material was resubjected as follows: To a dry hydrogenation bottle was added dry $\text{Pd}(\text{OH})_2/\text{C}$ (1500 mg) under an Ar atmosphere, followed by a solution of crude starting material (7700 mg, 23.5 mmol) in EtOH (400 mL). The mixture was degassed and refilled with H_2 3 times, then the mixture was stirred under a hydrogen atmosphere (50 Psi) at 50 °C for 48 hours. H-NMR showed the starting material was consumed completely, and the desired product was formed. The mixture was filtered through a pad of Celite® and the filtrate was concentrated to give the crude product. The crude product was combined with another batch for purification by silica gel column chromatography (0-33% EtOAc in DCM) to give the title compound (3.79 g, 34.6%) as a purple solid. ^1H NMR (400 MHz, CDCl_3) δ 7.15 (m, 1H) 6.86 - 6.98 (m, 1H) 6.54 - 6.80 (m, 2 H) 4.06 - 4.33 (m, 2 H) 3.68 (s, 3 H) 2.87 (t, $J=11.54$ Hz, 3 H) 1.99 (d, $J=12.05$ Hz, 2 H) 1.63 (d, $J=13.05$ Hz, 3 H) 1.43 - 1.53 (m, 10 H); LCMS: m/e 351.9 $[\text{M}+\text{Na}]^+$.

Step 3: tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate. To a round bottom flask was added tert-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate (2200 mg, 6.678 mmol), 4-fluorobenzenesulfonyl chloride (1950 mg, 10.0 mmol) and pyridine (30 mL). The solution was stirred at 15 °C for 13 hours. The reaction was combined with two other batches for workup. The solvent was removed under reduced pressure and the residue was partitioned with DCM (80 mL) and water (80 mL). The aqueous layer was extracted with DCM (40 mLx2). The combined organic layers were washed with aqueous citric acid and concentrated. The crude product was purified on by silica gel column chromatography (10-60% EtOAc in PE) to give the title compound (3.20 g, 55.6%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3): δ 7.70-7.66 (m, m2H), 7.27-7.26 (m, 1H), 7.15-7.05 (m, 3H), 6.84-6.81 (m, 2H), 6.39 (s, 1H), 4.20 (s, br, 2H), 3.72 (s, 3H), 2.88-2.82 (m, 3H), 1.92-1.89 (m, 2H), 1.58-1.51 (m, 2H), 1.50 (s, 9H) ppm. LCMS: m/e 510.0 $[\text{M}+\text{Na}]^+$.

Step 4: 4-fluoro-N-(1-methyl-3-(piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. To a solution of tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate (1200 mg, 2.461 mmol) in DCM (15 mL) was added HCl/dioxane (7 mL, 4 M) at 0-5 °C




in an ice/water bath. The brown solution was stirred at 20 °C for 2 hours. The reaction was combined with three other batches for workup. The solvent was removed under reduced pressure to give the crude product as a gum, which was then dissolved with MeOH and DCM. The resulting solution was concentrated to afford the title compound (3.67 g, 100%) as a brown solid. ¹H NMR (400 MHz, methanol-d₄) δ 7.70-7.67 (m, 2H), 7.36 (s, 1H), 7.22-7.15 (m, 3H), 7.06 (s, 1H), 6.80-6.78 (m, 1H), 3.77-3.68 (m, 4H), 3.52-3.49 (m, 2H), 3.37-3.12 (m, 4H), 2.22-2.18 (m, 2H), 1.97-1.86 (m, 2H) ppm. LCMS: *m/e* 388.0 [M+H]⁺.




Step 5: 4-fluoro-N-(3-(1-(isothiazole-5-carbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide. The title compound was prepared in an analogous manner to Example 1, step 10 employing isothiazole-5-carboxylic acid . LC/MS [M+H]⁺: 499; Rt = 2.93 (Method A).




Examples 7-18

The following Examples 7-18 were prepared in an analogous manner to Example 6 employing the necessary carboxylic acid in step 5.

Example	Structure	Name/Characterization
7		(R)-N-(3-(1-(2-cyclopentylpropanoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide; ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 9.77 (s, 1H), 7.70-7.67 (m, 2H), 7.37-7.32 (m, 2H), 7.23 (d, J=8.8 Hz, 1H), 7.12 (d, J=10.0 Hz, 1H), 7.08 (s, 1H), 6.80 (t, J=7.6 Hz, 1H), 4.52 (d, J=12.4 Hz, 1H), 4.08 (d, J=12.4 Hz, 1H), 3.65 (s, 3H), 3.17 (t, J=12.8 Hz, 1H), 2.89 (t, J=12.8 Hz, 1H), 2.67-2.65 (m, 2H), 1.99-1.0 (m, 16H); LC/MS [M+H] ⁺ :512
8		N-(3-(1-(cyclopropanecarbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. LC/MS [M+H] ⁺ : 456; Rt = 3.11 (method B)


Example	Structure	Name/Characterization
9		4-fluoro-N-(1-methyl-3-(1-(4,4,4-trifluoro-3-methylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. LC/MS $[M+H]^+$: 526; R_t = 3.27 (method A)
10		(R)-4-fluoro-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. 1H NMR (400 MHz, DMSO- d_6) δ ppm 9.76 (br. s., 1 H), 7.61 - 7.75 (m, 2 H), 7.36 (t, J =8.3 Hz, 2 H), 7.25 (d, J =9.0 Hz, 1 H), 7.02 - 7.17 (m, 2 H), 6.82 (d, J =8.53 Hz, 1 H), 4.60 (br. s., 1 H), 4.21 (d, J =12.05 Hz, 1 H), 3.66 (s, 3 H), 3.07 - 3.25 (m, 1 H), 2.54 - 2.95 (m, 3 H), 1.73 - 1.95 (m, 2 H), 1.21 - 1.52 (m, 2 H), 0.84 - 1.08 (m, 12 H); LCMS: m/e 522 $[M+Na]^+$.
11		N-(3-(1-(cyclobutanecarbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. 1H NMR (400 MHz, DMSO- d_6): δ 9.80 (s, 1H), 7.68-7.63 (m, 2H), 7.39-7.36 (m, 2H), 7.22-6.80 (m, 4H), 4.47-4.41 (m, 1H), 3.76-3.65 (m, 2H), 3.63 (s, 3H), 3.10-3.03 (m, 1H), 2.92-2.81 (m, 1H), 2.73-2.61 (m, 1H), 2.21-2.04 (m, 4H), 2.00-1.67 (m, 4H), 1.40-1.30 (m, 2H). LCMS: m/e 470.15 $[M+H]^+$

Example	Structure	Name/Characterization
12		4-Fluoro-N-(1-methyl-3-(1-(3-methylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. ^1H NMR (400 MHz, CDCl_3): δ 7.69-7.66 (m, 2H), 7.28-7.26 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.83-6.80 (m, 2H), 6.47 (bs, 1H), 4.76 (d, J = 13.2 Hz, 1H), 3.96 (d, J = 13.2 Hz, 1H), 3.71 (s, 3H), 3.17 (t, J = 12.4 Hz, 1H), 2.96-2.92 (m, 1H), 2.69 (t, J = 12.4 Hz, 1H), 2.26 (t, J = 6.8 Hz, 2H), 2.18-1.94 (m, 3H), 1.58-1.48 (m, 2H), 0.99 (t, J = 6.8 Hz, 6H). LCMS: m/e 472.20 $[\text{M}+\text{H}]^+$
13		N-(3-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. ^1H NMR (400 MHz, CDCl_3): δ 7.69-7.66 (m, 2H), 7.29 (d, J = 1.6 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 7.08-7.04 (m, 2H), 6.83 (d, J = 1.6 Hz, 1H), 6.81 (bs, 1H), 6.45 (bs, 1H), 4.76 (d, J = 13.2 Hz, 1H), 3.91 (d, J = 13.2 Hz, 1H), 3.71 (s, 3H), 3.19 (t, J = 12.0 Hz, 1H), 2.98-2.93 (m, 1H), 2.71 (t, J = 12.8 Hz, 1H), 2.32 (d, J = 6.8 Hz, 2H), 2.04-1.95 (m, 2H), 1.64-1.47 (m, 2H), 1.29-1.07 (m, 1H), 0.58 (d, J = 7.6 Hz, 2H), 0.20 (d, J = 4.8 Hz, 2H). LCMS: m/e 470.20 $[\text{M}+\text{H}]^+$
14		N-(3-(1-(cyclohexanecarbonyl)-piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 9.77 (s, 1H), 7.70-7.67 (m, 2H), 7.34 (t, J =8.8 Hz, 2H), 7.23 (d, J =8.8 Hz, 1H), 7.12 (d, J =2.0 Hz, 1H), 7.08 (s, 1H), 6.80 (dd, J =8.4, 2.0 Hz, 1H), 4.48 (d, J =13.2 Hz, 1H), 4.05 (d, J =13.2 Hz, 1H), 3.65 (s, 3H), 3.12-3.15 (m, 1H), 2.87-2.86 (m, 1H), 2.64-2.60 (m, 2H), 1.85-1.65 (m, 8H), 1.43-1.10 (m, 6H); LCMS: m/e 498.55 $[\text{M}+\text{H}]^+$

Example	Structure	Name/Characterization
15		<p>4-fluoro-N-(3-(1-(2-fluoro-6-methylbenzoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide. ^1H NMR (400 MHz, DMSO-d_6): δ 9.77 (s, 1H), 7.70-7.65 (m, 2H), 7.36-7.30 (m, 3H), 7.23 (d, $J=8.8$ Hz, 1H), 7.17-7.10 (m, 4H), 6.80 (dd, $J=8.4$, 1.2 Hz, 1H), 4.67 (d, $J=13.4$ Hz, 1H), 3.66 (s, 1.5H), 3.65 (s, 1.5H), 3.32-3.15 (m, 2H), 2.95-2.92 (m, 2H), 2.29 (s, 1.5H), 2.22 (s, 1.5H), 1.94 (d, $J=13.8$ Hz, 1H), 1.78 (d, $J=13.8$ Hz, 1H), 1.52-1.38(m, 2H); LCMS: m/e 524.55 $[\text{M}+\text{H}]^+$</p>
16		<p>(S)-N-(3-(1-(2,3-dimethylbutanoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. ^1H NMR (400 MHz, DMSO-d_6): δ 9.71 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.33 (m, 2H), 7.23 (d, $J=8.8$ Hz, 1H), 7.12 (d, $J=6.0$ Hz, 1H), 7.08 (s, 1H), 6.79 (d, $J=8.4$ Hz, 1H), 4.56-4.54 (m, 1H), 4.07 (d, $J=13.2$ Hz, 1H), 3.65 (s, 3H), 3.16 (t, $J=13.2$ Hz, 1H), 2.89 (d, $J=13.2$ Hz, 1H), 2.67-2.57 (m, 2H), 1.87-1.76 (m, 3H), 1.43-1.37 (m, 2H), 0.99-0.84 (m, 9H); LCMS: m/e 486.45 $[\text{M}+\text{H}]^+$</p>
17		<p>N-(3-(1-(cyclopentanecarbonyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-2-fluorobenzenesulfonamide ^1H NMR (400 MHz, CDCl_3): δ 7.70 (t, $J = 7.6$ Hz, 1H), 7.55-7.50 (m, 1H), 7.35 (s, 1H), 7.25-7.11 (m, 3H), 6.93 (t, $J = 7.6$ Hz, 1H), 6.78 (s, 1H), 6.70 (s, 1H), 4.75 (d, $J=13.6$ Hz, 1H), 4.07 (d, $J = 13.6$ Hz, 1H), 3.68 (s, 3H), 3.19 (t, $J=13.6$ Hz, 1H), 2.98-2.94 (m, 2H), 2.71 (d, $J=12.8$ Hz, 1H), 2.05-1.47 (m, 12H). LCMS: m/e 484.1 $[\text{M}+\text{H}]^+$</p>

Example 18

(R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide



5 Step 1: tert-butyl 2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate. To a RB flask charged with tert-butyl 2,2-dimethyl-4-oxopiperidine-1-carboxylate (7.76 g, 34.1 mmol) in dry THF (130 mL) was added slowly dropwise at -70 °C a solution of sodium bistrimethyldisilazide (7.51 g 41.0 mmol) in THF (41 mL). Upon complete addition, a solution of *N*-phenyltriflamide (16.1 g, 41.0 mmol) in THF (10 mL) was added and the mixture was allowed to
10 warm to room temperature over the course of 12 h. The reaction mixture was then concentrated and brought up in EtOAc:heptane (85:15, 100 mL) and washed twice with water. The combined organics were collected and concentrated to give 12.0 g (98%) of the titled compound as a yellow oil. ¹HNMR (400 MHz, CDCl₃) δ 5.78 (t, J=3.5 Hz, 1 H), 4.08 (q, J=2.7 Hz, 2 H), 2.40 (br s, 2 H), 1.37-1.58 (m, 14H).

15 Step 2: tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate. A mixture of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (prepared as described in Example 1) (1.25 g, 4.137 mmol), tert-butyl 2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate (1.63 g, 4.55 mmol) and K₃PO₄ (1.76 g, 8.27 mmol) in dioxane/H₂O (40 mL/4 mL) was purged and degassed with N₂ three
20 times. Pd(PPh₃)₄ (478 mg, 0.414 mmol) under nitrogen atmosphere was then added. The mixture was purged and degassed with N₂ for 5 mins and then heated to 60 °C overnight. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (0-66% EtOAc in PE =0-66%) to provide the title compound (1.45 g, 91.2%) as a yellow solid. ¹H
25 NMR (400 MHz, CDCl₃) δ ppm 8.83 (d, J=2.0 Hz, 1 H), 8.17 (dd, J=9.0, 2.0 Hz, 1 H), 7.34 (d, J=9.0 Hz, 1 H), 7.17 (s, 1 H), 6.35 (t, 1 H), 4.15 (d, J=4.0 Hz, 2 H), 3.85 (s, 3 H), 2.53 (s, 2 H), 1.43 - 1.56 (m, 9 H), 1.24 (s, 6 H).

Step 3: tert-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate. To a dry hydrogenation bottle was added Pd/C (200 mg) under Ar atmosphere, followed by a solution of tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridine-1(2H)-
30 carboxylate (1000 mg, 2.594 mmol) in EtOH (75 mL) and DCM (15 mL). The mixture was

degassed and purged with H₂ for 3 times and the mixture was stirred under hydrogen atmosphere (50 Psi) at 40 °C for 3 hours. The reaction solution was filtered through a pad of Celite® and the cake was washed with MeOH three times. The combined filtrate was concentrated to give the title compound (900 mg, 97%) as a lavender oil, which was used directly without further purification.

5 LCMS: *m/e* 380 [M+Na]⁺.

Step 4: tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate. To a solution of tert-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate (900 mg, 2.52 mmol) and 4-fluorobenzenesulfonyl chloride (735 mg, 3.78 mmol) in DCM (20 mL) was added TEA (764 mg, 7.55 mmol) and the mixture was stirred at 15 °C for 2 hours. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (10-25% EtOAc in PE) to give the title compound (1100 mg, 84.7 %) as a brown solid. LCMS: *m/e* 538 [M+Na]⁺.

Step 5: N-(3-(2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. To a solution of tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate (900 mg, 1.75 mmol) in DCM (25 mL) was added HCl/Dioxane (15 mL) and the resulting mixture was stirred for 6 hours at 15 °C. The solvent was removed under reduced pressure to give the title compound (800 mg, 100%) as a white solid, which was used directly without further purification. LCMS: *m/e* 416 [M+H]⁺.


Step 6: 4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide. To a suspension of N-(3-(2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide (400 mg, 0.885 mmol) in DCM (25 mL) was added TEA (269 mg, 2.65 mmol) at 0 °C. A solution of isobutyryl chloride (141 mg, 1.33 mmol) in DCM (5 mL) was added dropwise at 0 °C and stirred for 6 hours at this temperature. Additional TEA (134 mg, 1.32 mmol) and isobutyryl chloride (94 mg, 0.885 mmol) was added. The resulting mixture was stirred at 15 °C overnight. The reaction mixture was quenched with water, extracted with DCM (20mLx2). The combined organic layers were washed with brine, dried (Na₂SO₄), and the solvent was removed under reduced pressure. The crude product was purified by prep-HPLC (Column: YMC-Actus Triart, C18 150 x 30 mm, 5 µm; 52% MeCN/H₂O to 72% MeCN/H₂O, 0.225% formic acid) to give the title compound (207 mg, 40.2 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (br. s., 1 H), 7.69 (dd, *J*=8.8, 5.3 Hz, 2 H), 7.36 (t, *J*=8.8 Hz, 2 H), 7.28 (d, *J*=8.5 Hz, 1 H), 7.00 - 7.16 (m, 2 H), 6.88 (d, *J*=8.5 Hz, 1 H), 3.67 (s, 4 H), 2.78 - 3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48 - 1.74 (m, 3 H), 1.44 (d, *J*=12.6 Hz, 6 H), 0.84 - 1.06 (m, 6 H); LCMS: *m/e* 508.3 [M+Na]⁺.

Step 6: (R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide. The racemic 4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide (190 mg) was resolved by prep-SFC (Column: OJ, 250x30 mm, 5 µm; 25% EtOH/NH₃/H₂O; 60 mL/min) to give two peaks for which absolute

stereochemistry has been arbitrarily assigned. The first eluting isomer (7.33 min) was arbitrarily assigned as (S)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide (65 mg) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (br. s., 1 H), 7.69 (dd, *J*=8.8, 5.3 Hz, 2 H), 7.36 (t, *J*=8.8 Hz, 2 H), 7.28 (d, *J*=8.5 Hz, 1 H), 7.00 - 7.16 (m, 2 H), 6.88 (d, *J*=8.5 Hz, 1 H), 3.67 (s, 4 H), 2.78 - 3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48 - 1.74 (m, 3 H), 1.44 (d, *J*=12.6 Hz, 6 H), 0.84 - 1.06 (m, 6 H); LCMS: *m/e* 508 [M+Na]⁺. The second eluting isomer (7.57 min) was arbitrarily assigned as (R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide (90 mg) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.77 (br. s., 1 H), 7.69 (dd, *J*=8.8, 5.3 Hz, 2 H), 7.36 (t, *J*=8.8 Hz, 2 H), 7.28 (d, *J*=8.5 Hz, 1 H), 7.00-7.16 (m, 2 H), 6.88 (d, *J*=8.5 Hz, 1 H), 3.67 (s, 4 H), 2.78-3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48-1.74 (m, 3 H), 1.44 (d, *J*=12.6 Hz, 6 H), 0.84-1.06 (m, 6 H); LCMS: *m/e* 508 [M+Na]⁺.

Example 19

(R)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide



15


Step 1: N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. To a suspension of N-(3-(2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide (prepared as described in Example 18) (400 mg, 0.885 mmol) in DCM (25 mL) was added TEA (269 mg, 2.65 mmol) at 0 °C and the mixture was stirred until the solution turned clear. A solution of cyclopentanecarbonyl chloride (176 mg, 1.33 mmol) in DCM (5 mL) was added dropwise at 0 °C, and the mixture was stirred for 3 hours at this temperature. The reaction mixture was quenched with water and extracted with DCM (20 mLx2). The combined organic layers were washed with brine, dried (Na₂SO₄) and the solvent was removed under reduced pressure. The crude product was purified by prep-HPLC (Column: Phenomenex Gemini C18, 250x21.2 mm, 8 μm; 51% MeCN/H₂O to 71% MeCN/H₂O w/ NH₃ (pH 10)) to give the title compound (210 mg, 46.4 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.78 (br. s., 1 H), 7.69 (dd, *J*=8.5, 5.5 Hz, 2 H), 7.36 (d, *J*=17.6 Hz, 2 H), 7.28 (d, *J*=9.0 Hz, 1 H), 7.11 (s, 2 H), 6.87 (d, *J*=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, *J*=16.1 Hz, 6 H); LCMS: *m/e* 534.1 [M+Na]⁺.

25

Step 2: (R)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. The racemic N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide (200 mg) was resolved by prep-SFC (OJ (250x30 mm, 5 μ m; 28% MeOH, NH₃/H₂O, 60 mL/min) to give two peaks for which the absolute stereochemistry has been arbitrarily assigned. The first eluting isomer (4.99 min) was arbitrarily assigned as (S)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide (92 mg, 46 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.78 (br. s., 1 H), 7.69 (dd, *J*=8.53, 5.52 Hz, 2 H), 7.36 (d, *J*=17.6 Hz, 2 H), 7.28 (d, *J*=9.0 Hz, 1 H), 7.11 (s, 2 H), 6.87 (d, *J*=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, *J*=16.1 Hz, 6 H); LC/MS (*M*+Na) = 534.1; LCMS: *m/e* 534.1 [*M*+Na]⁺. The second eluting isomer (5.34 min) was arbitrarily assigned as (R)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide (95 mg, 48 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.78 (br. s., 1 H), 7.69 (dd, *J*=8.5, 5.5 Hz, 2 H), 7.36 (d, *J*=17.6 Hz, 2 H), 7.28 (d, *J*=9.0 Hz, 1 H), 7.11 (s, 2 H), 6.87 (d, *J*=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, *J*=16.1 Hz, 6 H); LC/MS (*M*+Na)⁺ = 534.1.

Example 20

Preparation of N-(3-((2S,4S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide



20

Steps 1: (S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-one. A flask with a mixture of benzyl (S)-2-methyl-4-oxopiperidine-1-carboxylate (500 mg, 2.02 mmol) and Pd/C (5% by weight, 215 mg) in EtOH (10 mL) was evacuated with water aspiration and then put under hydrogen gas. The mixture was stirred under 1.1 bar hydrogen over-pressure for 1h. The mixture was filtered through a Celite® plug, and the filtrate was concentrated in vacuo. To the residue was added DCM (10 ml) followed by triethylamine (1.41 mL, 10.1 mmol) and then cyclopentanecarbonyl chloride (492 μ L, 4.04 mmol) dropwise. The reaction mixture was stirred at room temperature for 1h, whereupon the reaction was quenched with 40 ml water followed by extraction in a phase separator (4 x DCM). The combined organic extracts were evaporated and the residue was purified by flash chromatography (EtOAc/heptane; 1:1) to provide the title compound (301 mg,

30

71%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.24-4.84 (2 br s, 1H), 4.64-4.10 (2 br s, 1H), 3.55-3.11 (2 br s, 1H), 2.95 (m, 1H), 2.65 (dd, J=6.7, 14.4Hz, 1H), 2.50-2.30 (m, 3H), 1.93-1.77 (m, 6H), 1.64-1.56 (m, 2H), 1.29-1.16 (m, 3H)

Step 2: (S)-1-(cyclopentanecarbonyl)-2-methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate. n-BuLi (2.5M solution in hexanes, 1.15 mL, 2.87 mmol) was added drop wise to diisopropylamine (402 μL, 2.87 mmol) in dry THF (5 mL) under nitrogen at -78 °C. The mixture was stirred at -78 °C for 30 min, whereupon (S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-one (300 mg, 1.43 mmol) in dry THF (4 mL) was added. The temperature was allowed to warm to room temperature. After stirring for 30 min, the reaction mixture was cooled to 0 °C. The mixture was quenched with NaHCO₃ (50% sat.) and extracted with diethyl ether. The organic phase was washed with citric acid (10%), NaOH (1M), water and brine. The organic phase was dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (EtOAc/heptane, 15:85 - 2:8) to provide the title compound (329 mg, 67%) as an orange oil. NMR showed the two double bond isomers. ¹H NMR (500 MHz, CDCl₃): δ 5.81-5.74 (m, 1H), 5.29-3.26 (m, 4H), 2.90-2.52 (m, 2H), 1.98-1.53 (m, 8H), 1.35-1.15 (m, 3H).


Step 3: (S)-cyclopentyl(2-methyl-4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methanone. A mixture of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (prepared as described in Example 1) (100 mg, 0.33 mmol), (S)-1-(cyclopentanecarbonyl)-2-methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate (119 mg, 0.35 mmol) and K₃PO₄ (155 mg, 0.73 mmol) in dioxane/water (9:1, 3 mL) was flushed with nitrogen. Tetrakis triphenylphosphine Pd(0) (38 mg, 0.03 mmol) was added, the vial was flushed quickly with nitrogen, and the mixture was stirred at 60 °C overnight. Water was added, and the mixture was extracted with DCM (4 x). The combined organic layers were concentrated in vacuo. The residue was purified by prep-HPLC to provide the title compound (110 mg, 90%) as a yellow glass. LCMS: m/e 368.20 [M+H]⁺

Steps 4: N-(3-((2S,4S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. A mixture of (S)-cyclopentyl(2-methyl-4-(1-methyl-5-nitro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methanone (50 mg, 0.14 mmol) and PtO₂ (6.1 mg, 0.027 mg) in EtOH/AcOH 6:1 (3.5 mL) was stirred at room temperature under H₂ (1 bar overpressure) for 18 h. The reaction mixture was filtered through a PTFE filter, and concentrated in vacuo. The reduced product was unstable and used immediately. The residue was dissolved in pyridine (3 mL). 4-Fluorobenzenesulfonyl chloride (40 mg, 0.20 mmol) was then added at room temperature, and the mixture was stirred for 90 min. The mixture was concentrated in vacuo, and the residue was purified by prep-HPLC to provide the title compound (3.7 mg, 5.5%). ¹H NMR (500 MHz, (CD₃)₂CO): δ 8.63 (s, 1H), 7.78-7.72 (m, 2H), 7.29-7.22 (m, 4H), 7.06 (s, 1H), 7.03-6.98 (m, 1H), 4.39-4.29 (m, 2H), 4.01 (br. s, 1H), 3.74 (s, 3H), 3.28 (br. S, 1H), 3.02 (quint., J = 8.43, 1H), 2.22-

2.13 (m, 1H), 2.01-1.95 (m, 1H), 1.94-1.52 (m, 10H), 1.11 (d, J = 6.45, 3H), LCMS: m/e 498.29 [M+H]⁺.

Example 21


Preparation of N-(3-((2S,4R)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide



Purification of the diastereomeric mixture produced in step 4 of Example 20 by preparative HPLC afford a second product as the title compound (6.3 mg, 9.3%). ¹H NMR (500 MHz, (CD₃)₂CO): δ 8.42 (s, 1H), 7.75 (q, J = 5.4, 8.4 Hz, 2H), 7.32-7.21 (m, 4H), 7.02 (s, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.99 (m, 0.5H), 4.59 (m, 0.5H), 4.50 (m, 0.5H), 4.00 (m, 0.5H), 3.73 (s, 3H), 3.42-2.98 (m, 3H), 2.0-1.51 (m, 12H), 1.40 (d, J = 6.7 Hz, 1.5H), 1.23 (d, J = 6.7 Hz, 1.5H), LCMS: m/e 498.28 [M+H]⁺.

Example 22

Preparation of 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3-methoxybenzenesulfonamide




Step 1: tert-butyl 4-(5-((4-fluoro-3-methoxyphenyl)sulfonamido)-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate. A solution of tert-butyl 4-(5-amino-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate (prepared as described in Example 6) (3.0 g, 9.1 mmol) and 4-fluoro-3-methoxybenzenesulfonyl chloride (2.5 g, 10.9 mmol) in dry pyridine (20 ml) was stirred at room temperature overnight. The pyridine was evaporated, and 1M HCl and DCM were added. The phases were separated and the organic layer was evaporated. The residue was purified by flash chromatography (heptane/EtOAc, 1:4) to provide the title compound (3.9 g, 82%). LCMS: m/e 518.33 [M+H]⁺.

Step 2: 4-fluoro-3-methoxy-N-(1-methyl-3-(piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. To a solution of tert-butyl 4-(5-((4-fluoro-3-methoxyphenyl)sulfonamido)-1-methyl-1H-indol-3-yl)piperidine-1-carboxylate (3.9 g, 7.5 mmol) in DCM (50 mL) was added TFA (5.7 mL), and the mixture was stirred at room temperature for 1 h. The volatiles were evaporated. The residue was dissolved in DCM, and sat. NaHCO₃ was added. The phases were separated and the organic layer evaporated to provide the title compound that was used in the subsequent step without further purification. LCMS: m/e 418.07 [M+H]⁺.


Step 3: 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3-methoxybenzenesulfonamide. To the crude 4-fluoro-3-methoxy-N-(1-methyl-3-(piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide from the previous step in dry pyridine (20 mL) was added isobutyryl chloride (4.7 mL, 44.7 mmol). The reaction mixture was stirred at room temperature for 1h. The pyridine was evaporated, and 1M HCl and DCM were added. The phases were separated and the organic layer was concentrated. The residue was purified by flash chromatography (heptane/EtOAc, 1:1) to provide the title compound (2.0 g, 55% over two steps). ¹H NMR (500 MHz, (CD₃)₂CO): δ 7.24-7.20 (m, 2H), 7.19-7.12 (m, 3H), 6.97 (s, 1H), 6.88 (dd, J = 2.0, 8.6 Hz, 1H), 4.67-4.62 (m, 1H), 4.16-4.10 (m, 1H), 3.71 (s, 3H), 3.66 (s, 3H), 3.26-3.22 (m, 1H), 3.03-2.95 (m, 2H), 2.81-2.73 (m, 1H), 2.03-1.91 (m, 1H), 1.62-1.48 (m, 2H), 1.35-1.22 (m, 2H), 1.13 (dd, J = 7.0, 10.9 Hz, 6H). LCMS: m/e 488.33 [M+H]⁺.

Example 23

Preparation of 4-fluoro-3-hydroxy-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)benzenesulfonamide



A solution of BBr₃ (24 mL, 1M in DCM) in was added to a stirred solution of 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3-methoxybenzenesulfonamide (prepared as described in Example 22) (1.97 g, 4.0 mmol) in DCM (30 mL) under an atmosphere of nitrogen at -78 °C. The cooling bath was removed and the mixture was stirred at room temperature for 1h. The reaction was quenched by adding MeOH (50 mL). Water and DCM were added and the phases were separated. The organic layer was concentrated and the residue was purified by prep-HPLC to provide the title compound (0.75 g, 39%). LCMS: m/e 474.33 [M+H]⁺.

Example 24**Preparation of (R)-4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3-((tetrahydrofuran-3-yl)oxy)benzenesulfonamide**




5 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3-methoxybenzenesulfonamide (prepared as described in Example 22) (30 mg, 0.06 mmol), (S)-tetrahydrofuran-3-ol (18 mg, 0.19 mmol), triphenylphosphine (25 mg, 0.10 mmol) and di-tert-butyl diazene-1,2-dicarboxylate (22 mg, 0.10 mmol) were charged in an oven-dried vessel under an atmosphere of nitrogen. Dry DCM (2 mL) was added, and the reaction mixture was stirred at room temperature overnight. The volatiles were evaporated and the residue was purified by prep-HPLC to provide the title compound (13 mg, 40%). ¹H NMR (500 MHz, CD₃OD): δ 7.40-7.36 (m, 1H), 7.27-7.21 (m, 2H), 7.12 (s, 1H), 6.99 (s, 1H), 6.90 (dd, J = 2.5, 9.0 Hz, 1H), 6.87-6.84 (m, 1H), 4.67-4.59 (m, 2H), 4.17-4.10 (m, 1H), 3.77-3.64 (m, 5H), 3.62-3.50 (m, 2H), 3.29-3.21 (m, 1H), 3.04-2.95 (m, 2H), 2.80-2.72 (m, 1H), 2.04-1.90 (m, 2H), 1.86-1.75 (m, 1H), 1.63-1.48 (m, 3H), 1.16-1.09 (m, 6H). LCMS: m/e 544.38 [M+H]⁺.





10

15

Examples 25-31

The following Examples 25-31 were prepared in an analogous manner to Example 22 employing the necessary benzenesulfonyl chloride in step 1 and the appropriate carboxylic acid in step 5.

Example	Structure	Name/Characterization
25		<p>(R)-4-methyl-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide; Rt = 5.02 (Method C); ¹H NMR (400 MHz, MeOD-<i>d</i>₄): δ 7.51-7.49 (m, 2H), 7.22-7.14 (m, 4H), 6.91 (s, 1H), 6.86-6.85 (m, 1H), 4.70-4.67 (m, 1H), 4.29-4.26 (m, 1H), 3.66 (s, 3H), 3.23-3.22 (m, 1H), 2.95-2.72 (m, 3H), 2.35 (s, 3H), 2.01-1.91 (m, 2H), 1.48-1.45 (m, 2H), 1.12-1.07 (m, 3H), 1.02-0.99 (m, 9H) ; LC/MS [M+H]⁺ :496.1</p>
26		<p>(R)-1,3,5-trimethyl-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)-1H-pyrazole-4-sulfonamide. Rt = 4.56 (Method C); ¹H NMR (400 MHz, MeOD-<i>d</i>₄): δ 7.25-7.21 (m, 2H), 6.98 (s, 1H), 6.89-6.87 (m, 1H), 4.74-4.71 (m, 1H), 4.34-4.31 (m, 1H), 3.72 (s, 3H), 3.62 (s, 3H), 3.33-3.28 (m, 1H), 2.91-2.78 (m, 3H), 2.11-2.00 (m, 8H), 1.64-1.54 (m, 2H), 1.14-1.11 (m, 3H), 1.09-1.01 (m, 9H); LC/MS [M+H]⁺: 514.1;</p>
27		<p>(R)-2-ethoxy-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. Rt =4.63 (Method D); ¹H NMR (400 MHz, MeOD-<i>d</i>₄): δ 7.65-7.62 (m, 1H), 7.45-7.26 (m, 2H), 7.12-7.09 (m, 2H), 6.92-6.84 (m, 3H), 4.69-4.66 (m, 1H), 4.30-4.28 (m, 3H), 3.66 (s, 3H), 3.30-3.21 (m, 2H), 2.93-2.72 (m, 3H), 1.99-1.96 (m, 2H), 1.55-1.46 (m, 5H), 1.12-0.99 (m, 12H). LC/MS [M+H]⁺ :526.1;</p>

Example	Structure	Name/Characterization
28		(R)-2-fluoro-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. Rt =4.91 (Method E); ¹ H NMR (400 MHz, MeOD- <i>d</i> ₄) δ ppm 7.66-7.64 (m, 1H), 7.58-7.54 (m, 1H), 7.27-7.13 (m, 4H), 6.94-6.91 (m, 2H), 4.70-4.67 (m, 1H), 4.31-4.28 (m, 1H), 3.64 (s, 3H), 3.31-3.24 (m, 1H), 2.97-2.73 (m, 3H), 2.08-1.90 (m, 2H), 1.73-1.46 (m, 2H), 1.55-1.46 (m, 5H), 1.12-0.99 (m, 12H) . LCMS: <i>m/e</i> 522.1 [M+Na] ⁺ .
29		(R)-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)benzenesulfonamide. LCMS: <i>m/e</i> 482.2 [M+H] ⁺
30		(R)-3,5-dimethyl-N-(1-methyl-3-(1-(2,3,3-trimethylbutanoyl)piperidin-4-yl)-1H-indol-5-yl)isoxazole-4-sulfonamide.). LCMS: <i>m/e</i> 501.1 [M+H] ⁺
31		(R)-N-(3-(1-(2-(bicyclo[1.1.1]pentan-1-yl)propanoyl)piperidin-4-yl)-1-methyl-1H-indol-5-yl)-4-fluorobenzenesulfonamide. LCMS: <i>m/e</i> 510.2 [M+H] ⁺

Example 36

Assay of co-activator recruitment by TR-FRET

The activity of compound of the invention can be determined by a co-activator recruitment by TR-FRET (time-resolved fluorescence resonance energy transfer) assay. In general, the assay is based on the interaction between N-terminally Six-Histidine-tagged-RORC2 ligand binding domain (6-His-RORC2 LBD), expressed in *E. coli* and purified by affinity chromatography, and
5 biotin-coactivator peptide SRC1-2 (biotin-aminohexanoic acid-CPSSHSSLTERHKILHRLQLQEGSPS-NH₂; SEQ ID NO: 1) containing the LXXLL consensus domain which is responsible for receptor binding. This interaction is detected by addition of Europium labeled-anti-His antibody (Ex. 337 nm, Em. 620 nm, which binds to 6His) and Streptavidin-APC (Ex. 620 nm, Em. 665 nm, which binds to biotin). When receptor and
10 coactivator are bound to each other, upon shining light at 337 nm on the sample, the Europium emits fluorescence that excites APC due to close proximity (FRET) and this signal is measured at 665 nm. Due to the long lasting fluorescence emission of Europium, the non-specific, short-lived fluorescence is time-resolved (TR) from the fluorescence of interest. Inhibitors of the interaction of receptor and coactivator peptide are detected by a decrease in TR-FRET signal.

Specifically, in one embodiment the aforementioned assay was performed as outlined below. The assay was carried out in black polystyrene, 384-well plates in a total assay volume of 50.5 μ L. The assay buffer contained 50 mM TRIS-HCL pH 7.5, 1 mM NaCl, 2 mM MgCl₂, 0.5 mg/mL bovine serum albumin, and 5 mM dithiothreitol. The final concentration of reagents was 6.3 nM RORC2 LBD, 200 nM SRC1-2, 50 nM streptavidin APC, 1 nM Europium-labeled anti-His
20 antibody, and varying concentrations of compounds such that final concentration of DMSO is 1% (v/v). The assay steps were: (1) dispensing 500 μ L compound at 100x final concentration in DMSO (test wells) or DMSO only (control wells for no inhibition); and (2) dispensing 50 μ L mixture of the other assay components including receptor (test wells) or excluding receptor (control wells for maximal inhibition).

Assay mixtures were incubated at room temperature for 3 hr and read in EnVision 2100 Multilabel Reader (PerkinElmer Life Sciences) at Excitation Filter 320, Emission Europium Filter 615, Emission APC Filter 665, Dichroic Mirror D400/D630.

TR-FRET signal was determined by calculating the ratio of 665 nm by 615 nm and IC₅₀ values of compounds of the invention (Table 1) were determined by the non-linear regression
30 analysis of dose response curves.

References which relate to the above-referenced assay include: Kallen et al. *Structure*, **2002**, 10, 1697-1707; Stehlin et al. *EMBO J* **2001**, 20, 5822-5831; and Zhou et al. *Mol Endocrinol* **1998**, 12, 1594-1604.

Table 1.

Example	IC ₅₀ (nM)
1	8.2
2	11.4
3	5.3
4	33.8
5	5.1
6	75.9
7	4.5
8	17.1
9	14.8
10	5.6
11	28.8
12	7.8

Example	IC ₅₀ (nM)
13	16.9
14	5.6
15	6.8
16	3.1
17	5.9
18	7.0
19	3.7
20	91.3
21	9.0
22	10.6
23	19.9
24	5.7

Example	IC ₅₀ (nM)
25	2.1
26	1.3
27	1.7
28	1.0
29	8.7
30	10.0
31	2.4
32	2.5
33	1.1
34	0.9
35	1.0

Example 37

Assay of Gal4-RORC2 activity by luciferase reporter

The activity of compound of the invention can be also be determined by a luciferase reporter Gal4-RORC2 activity assay. In general, Neuro2A cells (murine neuroblastoma cell line obtained from HPACC, cat #89121404) are transiently transfected with a mammalian expression vector (pM) containing Gal4-RORC2 LBD and a Gal4-responsive reporter gene containing firefly luciferase (5xGAL4UAS-Luc3). Gal4-RORC2 LBD is constitutively active in the transfected Neuro2a cells, resulting in a robust luciferase response in the absence of stimulation. Upon treatment with an RORC2 inhibitor the transcriptional response is decreased and the magnitude of the decrease in response is dose-dependently related to the intrinsic efficacy of the inhibitor.

Specifically, the growth medium was composed by MEM EBS w/o L-glutamine, 10% (v/v) FBS, 2 mM L-glutamine and 1x non-essential aminoacid (NEAA); the seeding medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1% Penicillin (10,000 U/mL)/Streptomycin (10,000 µg/mL); and the assay medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1% Penicillin (10,000 U/mL)/Streptomycin (10,000 µg/mL). In addition, Neuro2A cells were cultured in growth medium in humidified chambers at 37°C and 5% CO₂ using standard tissue culture procedures.

On day one of the assay, cells were seeded and transfected. Specifically, Neuro2A cells were suspended in seeding medium and mixed with plasmids and transfection reagent which was dissolved in OptiMEM I reduced serum medium (Invitrogen), and then seeded to 384-well plates

(Corning, Black, Clear bottom) in 40 μ L/well containing 12,500 cells, 17.25 ng Gal4-Luc3, 5.75 ng either empty pM vector ('no receptor control' wells) or pM-Gal4RORgamma-LBD, and 0.11 μ L Lipofectamine2000.

On day two of the assay, the cells were treated with compounds of the invention.

5 Specifically, the treatment was started 20-24 hr after seeding and transfection of the cells. Compounds of the invention were serially diluted in a 384-well polypropylene plate with assay medium containing 0.5% (v/v) DMSO at 5x final assay concentration. 10 μ L of the compounds (or 0.5% DMSO in assay medium for 'no compound control' wells) were transferred from the dilution plate to the 384-format cell plate such that final assay volume was 50 μ L and final DMSO
10 concentration was 0.1% (v/v), followed by incubation for 20-24 hr in humidified chambers at 37°C and 5% CO₂

On day three of the assay, luminescence was measured and the results analyzed.

Specifically, 10 μ L of SteadyLite Plus reagent (Perkin Elmer) was added to each well. The cell plates were incubated at room temperature for 15 min in the dark before reading of luminescence
15 on the MicroBeta Trilux (Wallac). IC₅₀ values of the compounds tested were determined by the non-linear regression analysis of dose response curves.

References which relate to the above-referenced assay include: Stehlin-Gaon et al. Nature Structural Biology **2003**, 10, 820-825; Wang et al. J Biol Chem. **2010**, 285(7), 5013-5025; Kumar et al. Mol Pharmacol. **2010**, 77(2), 228-36.

20 **Example 38**

Assay of IL-17 Production from human Th17 cells

The activity of compound of the invention can be also be determined by an IL-17 production from human Th17 cells assay. In general, this assay measures blockade of IL-17 production, the signature cytokine of T helper 17 (Th17) cells, by compounds. Purified human CD4+ T cells are
25 stimulated with anti-CD3 + anti-CD28 and incubated with a cytokine cocktail that induce their differentiation into Th17 in the absence or presence of various concentrations of compound. After 6 days, IL-17A concentration is measured in the cell culture supernatant with an ELISA kit (MSD).

Preparation of human CD4+ T cells. CD4+ T cells were purified from buffy coats from healthy donors (obtained from Massachusetts General Hospital) by negative selection the following
30 procedure: Mixing 25 mL of blood with 1 mL of Rosette Sep CD4+ T cell enrichment cocktail (StemCell Technologies) followed by application of a layer of 14 mL Ficoll Paque Plus (Amersham GE Healthcare) and subsequent centrifugation at 1200 g for 20 min at room temperature. The Ficoll layer was then harvested and washed with phosphate saline buffer containing 2% (v/v) fetal bovine serum and cells were resuspended with RPMI medium containing 10 % (v/v) fetal bovine
35 serum and 10% (v/v) DMSO, frozen and kept in LN2 until used.

On the first day of the assay, a vial containing 10^7 CD4⁺ T cells is thawed rapidly in 37°C water bath, immediately transferred into 20 mL X-Vivo 15 medium (Lonza), is spun for 6 min at 300xg, the supernatant is discarded, and the resulting pellet is re-suspended at 10^6 cells/mL in 50 mL fresh X-Vivo 15 medium, followed by storage overnight in a tissue culture vessel in a humidified chamber at 37°C and 5% CO₂. Serial dilutions of compounds of the invention are prepared at 10x final concentration in X-Vivo15 medium containing 3% (v/v) DMSO.

On the second day of the assay, a 384-well tissue culture plate was coated with 10 µg/mL anti-hCD3 (eBioscience) at 50 µL/well. After 2 hr at 37°C, the supernatant is discarded and the coated plates are kept in a sterile tissue culture hood.

Cytokine plus anti-CD28 cocktail is prepared by mixing 25 ng/mL hIL-6 (Peprotech), 5 ng/mL hTGFbeta1 (Peprotech), 12.5 ng/mL IL-1beta (Peprotech), 25 ng/mL hIL-21, 25 ng/mL hIL-23 (R&D Systems), and 1 µg/mL anti-hCD28 (eBioscience) in X-Vivo 15 medium. The cytokine plus anti-CD28 cocktail with CD4⁺ cells is prepared such that the cocktail is diluted 10-fold and cell density is 0.22×10^6 /mL. The mixture is incubated 1 hr at 37°C.

90 µL (20,000 cells) dispensed per well in the anti-hCD3 coated plate prepared as noted above.

10µL 10x compound is added per well (final DMSO=0.3%) from the compound plate that was previously prepared, followed by 6 days of incubation in a tissue culture vessel in a humidified chamber at 37°C and 5% CO₂.

On day six of the assay, production of IL-17A in 10 µL of the supernatant is determined by sandwich ELISA using 384w hIL17 MSD plates following the manufacturer's protocol. Measurement is carried out in a Sector Imager 6000 by the same manufacturer. Signal units from the instrument are converted to pg/mL using a calibration curve with known amounts of IL-17A. IC₅₀ values of test compounds (Table 2) are determined by the non-linear regression analysis of dose response curves.

A reference which relates to the above-referenced assay is: Yang et al. Nature **2008**, 454, 350-352.

Table 2.

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
1	13.5	6	275.7	11	148.0
2	4.8	7	28.1	12	126.6
3	121.1	8	183.6	13	309.6
4	137.0	9	99.1	14	221.2
5	90.3	10	29.0	15	188.6

Example	IC ₅₀ (nM)
16	53.8
17	114.4
18	19.0
19	191.3
20	633.0
21	88.7
22	267.1

Example	IC ₅₀ (nM)
23	1457.9
24	69.5
25	10.6
26	5.1
27	16.0
28	11.4
29	28.5

Example	IC ₅₀ (nM)
30	19.8
31	26.0
32	3.3
33	8.4
34	4.2
35	8.4

Example 39

Inhibition of Superantigen-induced Th17 cytokine production

Exotoxins called “superantigens” are among the most powerful T cell activators.

5 Superantigens bind to the cell surface of major histocompatibility complex (MHC) molecules, without intracellular processing. They stimulate T cells via the T cell receptor, irrespective of the antigen specificities. Therefore, bacterial superantigens are able to activate a large pool of CD4+ as well as CD8+ T cells in contrast to the low T cell frequency for conventional antigens. CD4+ T cells can be classified into various subsets (Th0, Th1, Th2, Th17) based on their respective

10 cytokine secretion profiles. Th0 cells are uncommitted naïve precursor cells that primarily produce IL-2 upon stimulation. Th0 cells upon activation can differentiate into Th1, Th2, or the Th17 subset depending on the local cytokine milieu. Th1 cells mainly produce Inf-γ; Th2 cells, IL-4, IL-5, and IL-13, and Th17 cells, IL-17, and IL-22. During a classical immune response, the differentiation of T helper subset occurs over days, or longer. In the superantigen in-vivo model in mice injection of

15 superantigen triggers a rapid transcription and translation of the various cytokines (i.e. IL-2, IL-4, Inf-γ, IL-17) of the different Th subsets after only 6 hr. A RORγt inhibitor given to animals prior to the superantigen stimulus would impair the Th17 cytokine profile without affecting the cytokine profile of the other Th subsets (Th0, Th1, Th2). The model uses approximately 8 week old C57BL/6, Balb/c, or C3H/HeJ mice which are dosed orally with compound 1 to 2 hr prior to

20 superantigen injection on the day of the experiment (Day 0) based on the pharmacokinetic (PK) profile of the compound. An optional dose may be given the day before superantigen injection (Day -1) to further inhibit the response if necessary. C57BL/6 and Balb/c mice will be sensitized 1 hr prior to supernatigen injection with approximately 25 mg/mouse D-Galactosamine intraperitoneally (C3H/HeJ mice do not need to be sensitized). Based on the literature superantigen is typically

25 given at 10 μg/mouse intraperitoneally. Mice will be sacrificed at 3 hr for RNA analysis or up to 6 hr for cytokine analysis.

A reference which relates to the above-referenced assay is: Rajagopalan, G. et. al. *Physiol Genomics* **2009**, 37, 279.

Example 40**Imiquimod Assay**

Commercially available 5% imiquimod (IMQ) cream (3M Pharmaceuticals) is applied to the back and right ear of each experimental mouse for two consecutive days. Control mice are treated similarly with a commercially available vehicle cream. The experimental mice are then administered with ROR γ t inhibitors, and the control mice with vehicle, for 4 days. The ear thickness is measured on all days by digital micrometer (Mitutoyo). Tissues, such as ears and spleens, are harvested on Day 5 for RNA analysis. Ear swelling and serum measurements are also made.

References describing aspects of this assay include: Van der Fits, L. et al. J. Immunol. **2009**, 182(9), 5836-45; Van Belle, A.B. et al. J Immunol. **2012**, 188(1), 462-9; Cai, Y. et al. Immunity **2011**, 35(4), 596-610; Fanti, P.A. et al. Int. J. Dermatol. **2006**, 45(12), 1464-5; Swindell, W.R. et al. PLoS One **2011**, 6(4), e18266; and Roller, A. et al. J. Immunol. **2012**, 189(9), 4612-20.

Example 41**IL-23 Injection Model of Mouse Skin Inflammation**

Ears from BALB/c mice were each injected intra-dermally every other day with 150 ng of mouse recombinant IL-23 (eBiosciences) or PBS in a total volume of 25 μ l. Ear swelling was measured in triplicate using a micrometer (Mitutoyo) right before each IL-23 challenge. On Day 14, mice were euthanized and ears were collected for measurement of cytokine levels, gene expression levels and histopathological evaluation. Mice were administered 3 - 100 mg/kg of an RORC2 modulator or vehicle once daily orally for the duration of the study. Alternatively, the RORC2 modulator was applied topically once or twice daily using a standard formulation (EtOH:propylene glycol:dimethyl isosorbide:DMSO, 38:30:15:15) at a concentration of 0.1% to 5.0%.


References describing aspects of this assay include: Muramoto, K. et al. J. Pharmacol. Exp. Ther. **2010**, 335(1), 23-31; Fridman, J. S. et al. J. Invest. Dermatol. **2011**, 131(9), 1838-1844.

INCORPORATION BY REFERENCE

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.


We claim:

1. A compound of Formula I:




or a pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, wherein,

X is phenyl or 5-membered heteroaryl, in each case optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃,



, -F, -Cl, -Br and -CN;

R¹ is -CH₃ or -CH₂CH₃;





W is , optionally substituted with one, two, three, four or five -CH₃; and


R² is (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl, phenyl or isothiazolyl, optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.


2. The compound of claim 1, wherein R¹ is -CH₃.













3. The compound of claim 1 or 2, wherein W is .




4. The compound of claim 1 or 2, wherein W is .




5. The compound of claim 1 or 2, wherein W is .


6. The compound of claim 1 or 2, wherein W is .
7. The compound of any one of claims 1-6, wherein X is phenyl substituted with one, two, three, four or five substituents independently selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN.
8. The compound of any one of claims 1-6, wherein X is 5-membered heteroaryl optionally substituted with one additional substituent selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OH, -OCH₂CH₂OCH₃, , -F, -Cl, -Br and -CN.
9. The compound of any one of claims 1-6, wherein X is , , , or .
10. The compound of any one of claims 1-6, wherein X is , or .
11. The compound of any one of claims 1-10, wherein R² is (C₁-C₆)alkyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of -F, -Cl, -Br, -OH, (C₁-C₃)alkyl, (C₁-C₃)haloalkyl and (C₃-C₁₀)cycloalkyl.
12. The compound of any one of claims 1-10, wherein R² is (C₁-C₆)alkyl.


13. The compound of any one of claims 1-10, wherein R^2 is methyl substituted with (C_3-C_6) cycloalkyl.
14. The compound of any one of claims 1-10, wherein R^2 is propyl substituted with $-CF_3$.
15. The compound of any one of claims 1-10, wherein R^2 is (C_3-C_{10}) cycloalkyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of $-F$, $-Cl$, $-Br$, $-OH$, (C_1-C_3) alkyl, (C_1-C_3) haloalkyl and (C_3-C_{10}) cycloalkyl.
16. The compound of any one of claims 1-10, wherein R^2 is unsubstituted (C_3-C_{10}) cycloalkyl.
17. The compound of any one of claims 1-10, wherein R^2 is phenyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of $-F$, $-Cl$, $-Br$, $-OH$, (C_1-C_3) alkyl, (C_1-C_3) haloalkyl and (C_3-C_{10}) cycloalkyl.
18. The compound of any one of claims 1-10, wherein R^2 is isothiazolyl optionally substituted with one, two, three, four or five substituents independently selected for each occurrence from the group consisting of $-F$, $-Cl$, $-Br$, $-OH$, (C_1-C_3) alkyl, (C_1-C_3) haloalkyl and (C_3-C_{10}) cycloalkyl.



20. The compound of claim 1, selected from the group consisting of







and pharmaceutically acceptable salts thereof.

21. A pharmaceutical composition comprising a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, admixed with a pharmaceutically acceptable carrier, excipient or dilutant.
22. A method of inhibiting RORC2 comprising of administering to a patient an effective amount of a pharmaceutical composition of claim 21.
23. A method for treating an immune disorder or inflammatory disorder comprising administering to a subject in need thereof a pharmaceutical composition of claim 22.
24. The method of claim 23, wherein the disorder is an inflammatory disorder.
25. The method of claim 23, wherein the disorder is an autoimmune disorder.
26. The method of claim 23, wherein the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile

rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodosa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, an immune disorder associated with or arising from activity of pathogenic lymphocytes, noninfectious uveitis, Behcet's disease, giant cell arteritis, nonalcoholic hepatic steatosis, or Vogt-Koyanagi-Harada syndrome.

27. A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-19 for use in medicine.
28. A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-19, or a pharmaceutical composition of claim 20, for use in treating or ameliorating an immune disorder or inflammatory disorder mediated by RORC2 and/or IL-17.
29. The use of claim 28, wherein the disorder is an inflammatory disorder.
30. The use of claim 28, wherein the disorder is an autoimmune disorder.
31. The use of claim 28, wherein the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis,

pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, an immune disorder associated with or arising from activity of pathogenic lymphocytes, noninfectious uveitis, Behcet's disease, giant cell arteritis, nonalcoholic hepatic steatosis, or Vogt-Koyanagi-Harada syndrome.

32. A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-20 for use in combination with another pharmaceutical agent.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2016/050477

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D401/04 A61K31/4439 A61P17/06 C07D401/14 C07D405/14
C07D413/14

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2015/015378 A2 (PFIZER [US]) 5 February 2015 (2015-02-05) claim 1	1-33
A	----- WO 2014/026330 A1 (MERCK SHARP & DOHME [US]; BARR KENNETH JAY [US]; MACLEAN JOHN [US]; ZH) 20 February 2014 (2014-02-20) claim 1	1-33
A	----- WO 2014/026329 A1 (MERCK SHARP & DOHME [US]; BARR KENNETH JAY [US]; BEINSTOCK COREY [US];) 20 February 2014 (2014-02-20) claim 1	1-33
A	----- WO 2014/026328 A1 (MERCK SHARP & DOHME [US]; BARR KENNETH JAY [US]; MACLEAN JOHN [US]; ZH) 20 February 2014 (2014-02-20) claim 1	1-33

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 March 2016

Date of mailing of the international search report

18/04/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bérillon, Laurent

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2016/050477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015015378 A2	05-02-2015	AU 2014298017 A1 CA 2919783 A1 SG 11201600200Q A TW 201516041 A US 2016046597 A1 UY 35687 A WO 2015015378 A2	11-02-2016 05-02-2015 26-02-2016 01-05-2015 18-02-2016 27-02-2015 05-02-2015
WO 2014026330 A1	20-02-2014	AU 2013302647 A1 CA 2881699 A1 EP 2920149 A2 JP 2015526444 A KR 20150041660 A US 2015218169 A1 WO 2014026330 A1 WO 2014028600 A2	26-02-2015 20-02-2014 23-09-2015 10-09-2015 16-04-2015 06-08-2015 20-02-2014 20-02-2014
WO 2014026329 A1	20-02-2014	AU 2013302727 A1 CA 2881693 A1 EP 2884977 A2 JP 2015526442 A KR 20150041659 A US 2015210687 A1 WO 2014026329 A1 WO 2014028591 A2	05-03-2015 20-02-2014 24-06-2015 10-09-2015 16-04-2015 30-07-2015 20-02-2014 20-02-2014
WO 2014026328 A1	20-02-2014	AU 2013302644 A1 CA 2881696 A1 EP 2884976 A2 JP 2015526443 A KR 20150041800 A US 2015191434 A1 WO 2014026328 A1 WO 2014028597 A2	05-03-2015 20-02-2014 24-06-2015 10-09-2015 17-04-2015 09-07-2015 20-02-2014 20-02-2014